63. Idiopathic thrombocytopenic purpura Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 868 / Drugs : 544 - (DrugBank : 96) / Drug target genes : 82 - Drug target pathways : 195
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
10-MG dose OF E5501 2G tablet
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501 cyclodextrin oral solution
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501 lipid-based oral
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501-P21% powder
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
5% (5G/100 ML) intravenous immunoglobin
On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.
2025 Phase 3 NCT06962631 Brazil
Acetaminophen and diphenhydramine only product
Baylor College of Medicine
2021 Phase 1 NCT04741139 United States
Acetominophen
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Acetylcysteine
Peking University People's Hospital
2019 Phase 2 NCT04368598 China
2018 Phase 1/Phase 2 NCT03460808 China
Acide ACétylsalicylique
CHU Toulouse
2021 Phase 4 EUCTR2020-000968-30-FR France
ACT-HIB polvere E solvente PER soluzione iniettabile IN siringa preriempita 0,5 ML
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
AKR-501, YM-477
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
Alemtuzumab, rituximab
Hospital Universitario Dr. Jose E. Gonzalez
2008 Phase 2/Phase 3 NCT00749112 Mexico
ALL trans retinoic acid
Peking University People's Hospital
2020 Phase 2 NCT04618328 China
ALL-trans retinoic acid
Peking University People's Hospital
2026 Phase 3 NCT07597395 China
2017 Phase 2 NCT03304288 China
2012 Phase 2 NCT01667263 China
ALL-trans-retinoid acid
First Affiliated Hospital of Suzhou Medical College
2011 - NCT01668615 China
AMG 531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
Amgen
2007 Phase 3 NCT00603642 Japan
2007 Phase 1/Phase 2 NCT00515203 Australia;Canada;Spain;United States
2005 Phase 3 NCT00102336 United States
2005 Phase 3 NCT00102323 France;Netherlands;Spain;United States
Amgen Inc
2015 Phase 3 EUCTR2011-005019-96-PL Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-HU Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-GB Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-CZ Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-BE Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2005 Phase 3 EUCTR2004-000174-31-GB Spain;United Kingdom
2005 - EUCTR2004-000174-31-ES Spain;United Kingdom
2005 Phase 3 EUCTR2004-000173-65-GB Spain;United Kingdom
2005 - EUCTR2004-000173-65-ES Spain;United Kingdom
- - EUCTR2011-005019-96-Outside-EU/EEA Australia;Brazil;Canada;Israel;Mexico;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
- Phase 3 EUCTR2011-005019-96-FR Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
- Phase 3 EUCTR2011-005019-96-ES Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2007-000638-37-IE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 Phase 3 EUCTR2004-000172-13-GB Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-DE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-CZ Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-BE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-AT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2007 Phase 2 EUCTR2007-003569-42-ES Spain
2007 - EUCTR2006-003700-18-PT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
- - EUCTR2010-018426-39-Outside-EU/EEA Australia;Canada;United States
- - EUCTR2009-016203-32-Outside-EU/EEA Australia;Canada;United States
AMG531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2004-000172-13-IT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
Amifostine
The First Affiliated Hospital of Dalian Medical University
2014 - ChiCTR-TRC-14004514 China
Aminophylline
Department of Hematology, The First Affiliated Hospital of Soochow University
2017 - ChiCTR-ONC-17013230 China
Amoxicillin
Assiut University
2020 Phase 4 NCT03172676 Egypt
Amoxicillin hydrate
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
ANTI-CD20 monoclonal antibody and THE BTK inhibitor
Qi deng
2026 Phase 1 NCT07574073 -
ANTI-CD38 antibody injection
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 2 NCT06168851 China
ANTI-CD40L
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
ANTI-CD40ldab
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
ANTI-D
University of Aarhus
2004 Phase 2 NCT00128882 Denmark
ANTI-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006055 United States
Aprednisolon
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
ARGX-113
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
Gandini Domenica
2022 Phase 3 JPRN-jRCT2071210087 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Latvia;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
argenx
2017 Phase 2 NCT03102593 Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
Aspirin
Peking Union Medical College Hospital
2024 Phase 2 NCT06478537 China
University Hospital, Toulouse
2023 Phase 2 NCT04912505 France
Atorvastatin
Peking University People's Hospital
2018 Phase 1/Phase 2 NCT03460808 China
Atorvastatin 10MG
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China
Atorvastatin 20MG
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China
Atorvastatin 40 MG oral tablet + N-acetylcysteine 400 MG oral tablet
Hospital Civil de Guadalajara
2018 Early Phase 1 NCT05551624 Mexico
Atra
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Peking University People's Hospital
2026 Phase 3 NCT07597395 China
2020 Phase 2 NCT04217148 China
Shandong University
2013 Phase 3 NCT01882127 China
Autologous ANTI-bcma chimeric antigen receptor T cells
The First Affiliated Hospital of Soochow University
2022 Phase 2 NCT05315778 China
Autologous peripheral blood stem cell transplantation
Fairview University Medical Center
2000 - NCT00006055 United States
Avatrombopag
Eisai Inc.
2012 Phase 3 NCT01438840 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 NCT01433978 United States
Eisai Limited
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
Fuyang People's hospital
2024 Phase 4 ChiCTR2500095156 China
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06281327 China
2021 Phase 2 NCT04993885 China
Ostfold Hospital Trust
2025 Phase 3 NCT07051915 -
Shandong University
2021 - NCT04949009 China
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
Shimizu Yasuko
2022 Phase 3 JPRN-jRCT2031220005 -
Sobi, Inc.
2021 Phase 3 NCT04516967 France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Swedish Orphan Biovitrum
2022 - NCT04943042 Croatia;Czechia;Germany;Ireland;Italy;Netherlands;Norway;Spain;Switzerland;United Kingdom
Avatrombopag 20 MG oral tablet
Al-Mustansiriyah University
2025 Phase 4 NCT07133659 Iraq
Dova Pharmaceuticals
2021 Phase 3 NCT05046327 -
Avatrombopag maleate
Dova Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Sobi, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE France;Germany;Hungary;Poland;Russian Federation;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Avatrombopag oral tablet
Sobi, Inc.
2022 Phase 3 NCT05369208 Japan
2021 Phase 4 NCT04638829 United States
Avatrombopag tablets
Eisai Inc.
2007 Phase 2 NCT00625443 United States
2007 Phase 2 NCT00441090 United States
Avatrombopag+ALL trans retinoic acid
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2/Phase 3 NCT07278908 -
Azathioprine
Assiut University
2017 Phase 4 NCT03229746 Egypt
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China
B02bx05
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Baricitinib
Peking University People's Hospital
2022 Phase 2 NCT05446831 China
Baricitinib 2 MG
Peking University People's Hospital
2023 Phase 2 NCT05932524 China
2023 Phase 2 NCT05852847 China
BCMA-CD19 ccar T cells
iCell Gene Therapeutics
2024 Phase 1 NCT06787989 China
Belantamab mafodotin
Hellenic Society of Hematology
2025 Phase 2 NCT07019545 Greece
Belimumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2022 Phase 3 EUCTR2021-000006-16-FR France;Italy;Norway;Spain
Assistance Publique - Hôpitaux de Paris
2017 - NCT03154385 France
GlaxoSmithKline
2013 Phase 2 NCT01440361 Germany;United Kingdom
GlaxoSmithKline Research & Development Limited
2012 - EUCTR2011-000241-21-DE Germany;United Kingdom
2011 - EUCTR2011-000241-21-GB Germany;United Kingdom
The Second Affiliated Hospital of Kunming Medical University
2022 - ChiCTR2200058433 China
Benlysta
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2022 Phase 3 EUCTR2021-000006-16-FR France;Italy;Norway;Spain
Assistance Publique - Hôpitaux de Paris
2017 - NCT03154385 France
GlaxoSmithKline Research & Development Limited
2012 - EUCTR2011-000241-21-DE Germany;United Kingdom
2011 - EUCTR2011-000241-21-GB Germany;United Kingdom
Bexsero – sospensione iniettabile – siringa preriempita
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
BI 655064
Boehringer Ingelheim
2013 Phase 1 NCT02009761 United States
Biological tests
University Hospital, Brest
2015 - NCT02891109 France
Biological: M254
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
BIVV009 6.5 grams
Bioverativ, a Sanofi company
2017 Phase 1 NCT03275454 Germany;United Kingdom;United States
BIVV009 7.5 grams
Bioverativ, a Sanofi company
2017 Phase 1 NCT03275454 Germany;United Kingdom;United States
BIVV020
Bioverativ, a Sanofi company
2021 Phase 2 NCT04669600 Czechia;Germany;Netherlands;Spain;United Kingdom;United States
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004162-18-NL Austria;Belgium;Czech Republic;Czechia;Germany;Netherlands;Spain;United Kingdom
2021 Phase 2 EUCTR2020-004162-18-ES Austria;Belgium;Czech Republic;Czechia;Germany;Netherlands;Spain;United Kingdom
2021 Phase 2 EUCTR2020-004162-18-DE Austria;Belgium;Czech Republic;Czechia;Germany;Netherlands;Spain;United Kingdom
2021 Phase 2 EUCTR2020-004162-18-CZ Austria;Belgium;Czech Republic;Czechia;Germany;Netherlands;Spain;United Kingdom
Blisibimod
Anthera Pharmaceuticals
2015 Phase 2/Phase 3 NCT01609452 -
Blood draw FOR future biomarker analysis
Genzyme, a Sanofi Company
2019 Phase 4 NCT03784898 United States
Blood sample
Assistance Publique - Hôpitaux de Paris
2012 - NCT02287649 France
Centre Hospitalier Universitaire Dijon
2014 - NCT02821572 France
University Hospital, Bordeaux
2019 - NCT04005638 France
Blood samples
Centre Hospitalier Universitaire Dijon
2011 - NCT02042560 France
University Hospital, Bordeaux
2021 - NCT04800458 France
2009 - NCT04071496 -
BMS-986004
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
BMS-986004 1500 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 225 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 675 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 75 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986353
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2026 Phase 2 NCT07603557 Denmark;Germany;United Kingdom;United States
BMS-986413
Imperial College Healthcare NHS Trust
2021 Phase 2 NCT05393999 United Kingdom
BMS-986414
Imperial College Healthcare NHS Trust
2021 Phase 2 NCT05393999 United Kingdom
Bortezomib
Fujian Children's Hospital
2022 Phase 0 ChiCTR2200061828 China
Seoul National University Hospital
2023 Phase 2 NCT05599880 South Korea
Shandong University
2018 Phase 3 NCT03443570 China
2017 Phase 2 NCT03013114 China
BT595
Biotest
2016 Phase 3 NCT02859909 Bulgaria;Czechia;Germany;Hungary;Serbia;Spain
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
BU zhong YI QI tang, ZHI XUE tang, chuan XIN lian kang YAN pian MOD, tian wang BU XIN DAN
Hadassah Medical Organization
2011 Phase 2/Phase 3 NCT01226524 Israel
Budoprutug
Climb Bio, Inc.
2025 Phase 1/Phase 2 NCT07043946 Bulgaria;Greece;Serbia;Spain;Ukraine
Bélimumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2022 Phase 3 EUCTR2021-000006-16-FR France;Italy;Norway;Spain
Caffeic acid
Shandong University
2012 Phase 3 NCT02351622 China
Caffeic acid tablets
Shandong University
2015 Phase 4 NCT02556814 China
Caplacizumab
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
CAR-T cells
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
2024 Phase 1/Phase 2 NCT06352281 China
Shanghai Cell Therapy Group Co.,Ltd
2025 Early Phase 1 NCT07174843 China
Cart infusion
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026 Early Phase 1 NCT07441525 China
CC312
CytoCares Inc
2024 Early Phase 1 NCT06888960 China
CD19 and BCMA-targeted allogeneic CAR-T cells
The First Affiliated Hospital of Soochow University
2025 Phase 1 NCT07072247 China
CD19 UCAR-T cells
Institute of Hematology & Blood Diseases Hospital, China
2026 - NCT07212322 China
CD4-IGG
Genentech, Inc.
1997 Phase 1 NCT00002250 United States
Cevidoplenib
Oscotec Inc.
2021 Phase 2 EUCTR2018-003329-26-PL Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 EUCTR2018-003329-26-GR Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 EUCTR2018-003329-26-ES Greece;Korea, Republic of;Poland;Spain;United States
Chidamide
Shandong University
2022 Phase 2 NCT05411874 -
2021 Phase 1/Phase 2 NCT03838354 China
CID-103
CASI Pharmaceuticals, Inc.
2025 Phase 1/Phase 2 NCT07017725 China
Clarithromycin
Assiut University
2020 Phase 4 NCT03172676 Egypt
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
CM313 injection
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06199089 China
2023 Phase 2 NCT05694767 China
Keymed Biosciences Co.Ltd
2024 Phase 2 NCT06594146 China
CM336 injection
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06799611 China
Keymed Biosciences Co.Ltd
2025 Phase 1/Phase 2 NCT07175493 China
CNCT19 cell injection
Peking Union Medical College Hospital
2023 Early Phase 1 NCT05930314 China
Collection OF biological samples
University Hospital, Bordeaux
2011 Phase 3 NCT04070599 France
Combination OF rituximab with subcutaneous belimumab
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT05338190 France
Combined USE OF TPO-RAS with LOW-dose ANTI-CD20 antibody
Institute of Hematology & Blood Diseases Hospital, China
2021 Phase 2/Phase 3 NCT04915482 China
Complete blood picture
Assiut University
2017 - NCT03244410 -
Conventional
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt
Subei People's Hospital of Jiangsu province.
2025 Phase 2 ChiCTR2500105480 China
Corticosteriod FOR treated patients
Assiut University
2023 - NCT04482777 -
Corticosteroids
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria
Novartis Pharmaceuticals
2023 Phase 3 NCT05653349 Argentina;Australia;Austria;Belgium;Bulgaria;China;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey (Türkiye);United Kingdom;United States;Vietnam
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China
Corticosteroids combined with immunoglobulin and romiplostim
Wuhan Union Hospital, China
2024 Phase 2 NCT06686927 China
CTX112
CRISPR Therapeutics AG
2026 Phase 1/Phase 2 NCT07549698 Spain;United States
Cyclophosphamide
Fairview University Medical Center
2000 - NCT00006055 United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2026 Phase 2 NCT07603557 Denmark;Germany;United Kingdom;United States
Cyclosporin A
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Shandong University
2014 Phase 3 NCT02203422 China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China
Cyclosporine
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-OIC-17012860 China
Fairview University Medical Center
2000 - NCT00006055 United States
The First Affiliated Hospital of Zhejiang Chinese Medical University
2026 - ChiCTR2600125760 China
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China
The Second Affiliated Hospital of Kunming Medical University
2022 - ChiCTR2200058433 China
2020 Phase 4 ChiCTR2000030603 China
Zhejiang Provincial Hospital of Traditional Chinese Medicine
2022 Phase 0 ChiCTR2200062120 China
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China
Cytokine essays
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Daclizumab
National Institutes of Health Clinical Center (CC)
2002 Phase 2 NCT00049725 United States
Danazol
Peking University People's Hospital
2023 Phase 2 NCT06176911 China
2023 Phase 2 NCT05852847 China
2021 Phase 2 NCT05353673 China
2021 Phase 2 NCT05281068 China
2020 Phase 2 NCT04481282 China
2018 Phase 1/Phase 2 NCT03460808 China
2012 Phase 2 NCT01667263 China
Peking University People's Hospital, Peking University Institute of Hematology
2012 - ChiCTR-TRC-12002424 China
Second Affiliated Hospital of Dalian Medical University
2018 - ChiCTR1800016177 China
Dapsone
Assistance Publique - Hôpitaux de Paris
2015 Phase 3 NCT02627417 France
Daratumumab
Institute of Hematology & Blood Diseases Hospital, China
2026 Phase 2 NCT07362238 China
2026 Phase 2 NCT07362199 China
2026 Phase 2 NCT07297563 China
2026 Phase 2 NCT07234019 China
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
the First Affiliated Hospital of University of Science and Technology of China
2024 Phase 0 ChiCTR2400091558 China
Daratumumab injection
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT07063199 China
2024 Phase 2 NCT06838962 China
2022 Phase 2 NCT05562882 China
Ostfold Hospital Trust
2021 Phase 2 NCT04703621 Denmark;France;Norway
Darzalex
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
Decitabine
Shandong University
2018 Phase 3 NCT03252457 China
2015 Phase 2 NCT01568333 China
Desametasone 40MG
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
DEX combined with RTX, CSA and ivig
Shandong University
2016 Phase 3 NCT02834468 China
Dexamethasone
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-IIR-17012850 China
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
Fujian Medical University Union Hospital
2022 Phase 4 NCT05522465 China
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Hellenic Society of Hematology
2025 Phase 2 NCT07019545 Greece
Hoffmann-La Roche
2005 Phase 3 NCT00770562 Italy
Hospital Universitario Dr. Jose E. Gonzalez
2015 Phase 2 NCT02834286 Mexico
Inner Mongolia International Mongolian Medical Hospital
2023 Phase 1 ChiCTR2300074376 China
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
Novartis Pharma GmbH
2020 Phase 2 EUCTR2019-002658-21-DE Germany
Novartis Pharmaceuticals
2020 Phase 2 NCT04346654 Germany
Ostfold Hospital Trust
2016 Phase 3 NCT03010202 Norway
Peking University People's Hospital
2025 Phase 2 NCT07065968 China
2025 Phase 2 NCT07064889 China
2023 Phase 2 NCT06176235 China
2023 Phase 2 NCT05932524 China
2022 Phase 2 NCT05369364 -
2021 Phase 2 NCT04747080 China
2020 Phase 2 NCT04217148 China
2019 Phase 2 NCT04368598 China
2016 Phase 2/Phase 3 NCT02751593 -
Shandong University
2021 Phase 2 NCT05023915 China
2021 Phase 2/Phase 3 NCT03692754 China
2020 - NCT04320225 -
2020 Phase 4 NCT04094805 China
2019 Phase 4 NCT03998982 China
2018 Phase 3 NCT03252457 China
2017 Phase 2 NCT03033199 China
2016 Phase 2 NCT01965626 China
2015 Phase 4 NCT02642380 China
2015 Phase 4 NCT02556814 China
2014 Phase 2 NCT02153060 China
2013 Phase 2 NCT01976195 China
2013 Phase 3 NCT01882127 China
2012 Phase 3 NCT02351622 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2010 Phase 4 NCT01356511 China
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
The Second Affiliated Hospital of Army Military Medical University
2022 Phase 4 ChiCTR2100052913 China
University Hospital, Essen
2002 Phase 3 NCT02334813 -
University Hospital, Macau
2015 - ChiCTR1900021211 China
Weill Medical College of Cornell University
2016 Phase 3 NCT02649504 -
Zhejiang Provincial Hospital of Traditional Chinese Medicine
2022 Phase 1 ChiCTR2200058259 China
Dexamethasone abcur
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Dexamethasone acetate
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2021 Phase 3 EUCTR2021-000292-37-FR France
Dexamethasone and rituximab
Copenhagen University Hospital at Herlev
2004 Phase 3 NCT00909077 Denmark
Dexamethasone combined with romiplostim N01
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06658834 China
Dexamethasone monotherapy
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06992128 China
2024 Phase 2 NCT06658834 China
Dexamethasone oral
Yunfeng Cheng
2024 - NCT06479317 China;Hong Kong;Macau
Dexamethasone palmitate
Nakayama Takayuki
2019 Phase 1 JPRN-jRCTs041190069 -
Dexamethasone USP micronized
New England Research Institutes
2010 Phase 3 NCT00991939 United States
Diammonium glycyrrhizinate enteric-coated capsule
Shandong University
2021 Phase 2 NCT05023915 China
Difenidramina cloridrato
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Discontinuation OF eltrombopag
Weill Medical College of Cornell University
2011 - NCT01386723 United States
Doptelet 20 MG FILM-coated tablets
Dova Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Sobi, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE France;Germany;Hungary;Poland;Russian Federation;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Doxil
Hematology and Oncology Specialists
2001 Phase 2 NCT00107913 United States
Drug therapy FOR ITP
Ain Shams University
2013 Phase 2/Phase 3 NCT01763658 Egypt
Dyphenhydramine hydrochloride
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
DZD8586 dose level 1
Dizal Pharmaceuticals
2026 Phase 2 NCT07294365 China
DZD8586 dose level 2
Dizal Pharmaceuticals
2026 Phase 2 NCT07294365 China
DZD8586 dose level 3
Dizal Pharmaceuticals
2026 Phase 2 NCT07294365 China
E5501
Eisai Inc.
2011 Phase 1 NCT01437384 United States
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
E5501 40 MG 2 X 20-MG tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
E5501 40 MG 2 X 20-MG tablets, orally, with food
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
E5501 40MG 2 X 20-MG tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
Efgartigimod
ARGENX BV
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom
Jaume Ayguasanosa
2020 Phase 3 JPRN-jRCT2011220037 Austria;Belgium;Bulgaria;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russia;Spain;The Czech Republic;The Netherlands;The United Kingdom;The United States;Turkey;Ukraine
argenx
2020 Phase 3 NCT04274452 United States
2020 Phase 3 NCT04225156 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russia;Spain;Turkey (Türkiye);Ukraine;United Kingdom;United States
2019 Phase 3 NCT04188379 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BV
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod alfa
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
Gandini Domenica
2022 Phase 3 JPRN-jRCT2071210087 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Latvia;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
Efgartigimod alpha
argenx BVBA
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod IV
argenx
2025 Phase 2/Phase 3 NCT07194850 Germany;Italy;Poland;Romania;Spain;United Kingdom
2024 Phase 3 NCT06544499 Austria;Bulgaria;China;Croatia;Czechia;France;Germany;Hungary;Ireland;Italy;Poland;Portugal;Romania;Serbia;Spain;United Kingdom;United States
Efgartigimod PH20 SC
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx
2021 Phase 3 NCT04812925 Argentina;Australia;Bulgaria;Chile;China;Georgia;Greece;Ireland;Italy;Japan;Jordan;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russia;South Africa;South Korea;Thailand;Tunisia;Turkey (Türkiye);United Kingdom;United States
2020 Phase 3 NCT04687072 Argentina;Australia;Bulgaria;Chile;China;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
Eltrombopag
Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan
2016 Phase 3 NCT02877212 Pakistan
Assiut University
2019 Phase 4 NCT04102033 -
Baylor College of Medicine
2019 Phase 3 NCT03939637 United States
Beijing Children Hospital, Capital Medical University
2021 Phase 4 ChiCTR2100048162 China
Eisai Inc.
2012 Phase 3 NCT01433978 United States
Fuyang People's hospital
2024 Phase 4 ChiCTR2500095156 China
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline
2012 Phase 3 NCT01520909 Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2010 - NCT01439321 -
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
2009 - NCT01236014 -
2009 Phase 2 NCT00908037 Canada;France;Netherlands;Spain;United Kingdom;United States
2007 Phase 2 NCT00424177 Australia;Canada;Germany;India;Korea, Republic of;Netherlands;Russian Federation;Spain;Tunisia;United Kingdom;United States
2006 Phase 3 NCT00370331 Austria;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;Ukraine;United Kingdom;United States;Vietnam
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2004-000367-98-DK Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-SE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-EE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 Phase 2 NCT02402998 Italy
2016 - NCT02298075 Italy
Hagaziekenhuis
2017 Phase 4 EUCTR2016-004295-22-NL Canada;Netherlands
Hematology/ Oncology, Iwate Medical University
2013 - JPRN-UMIN000011396 Japan
Hospital Universitario Dr. Jose E. Gonzalez
2015 Phase 2 NCT02834286 Mexico
Humanity & Health Medical Group Limited
2018 Phase 2 NCT03830749 Hong Kong
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria
Institute of Hematology & Blood Diseases Hospital, China
2022 Phase 4 NCT05583838 China
2018 Phase 2 NCT03664518 China
Jikei University school of Medicine
2011 - JPRN-UMIN000006150 Japan
McMaster University
2012 Phase 3 NCT01621204 Canada;Netherlands
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Novartis Pharma. K.K.
2020 Phase 2 JPRN-jRCT2080225175 Asia except Japan;Europe;Japan;North America;South America
Novartis Pharmaceuticals
2023 Phase 3 NCT05653219 Argentina;Australia;Austria;Belgium;China;Czechia;France;Germany;Hungary;India;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;South Korea;Spain;Taiwan;Thailand;Turkey (Türkiye);United Kingdom;United States
2020 Phase 2 NCT04346654 Germany
2018 Phase 2 NCT03524612 Austria;Brazil;Chile;France;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
2010 - NCT01416311 -
Peking University People's Hospital
2022 Phase 2 NCT05369377 China
2020 Phase 1 NCT04518878 China
2020 Phase 2 NCT04516837 China
2020 - NCT04214951 China
Shanghai Sixth People's Hospital
2019 Phase 4 ChiCTR1900021755 China
Sohag University
2025 - NCT07093606 Egypt
The First Affiliated Hospital of Zhejiang Chinese Medical University
2026 - ChiCTR2600125760 China
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China
The Second Affiliated Hospital of Kunming Medical University
2021 Phase 4 ChiCTR2100051890 China
2020 Phase 4 ChiCTR2000030603 China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025 Phase 4 NCT07189910 China
University Hospital, Macau
2015 - ChiCTR1900021211 China
Weill Medical College of Cornell University
2013 Phase 2 NCT01880047 United States
2009 Phase 2 NCT00902018 United States
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China
Yamauchi Kyosuke
2023 Phase 3 JPRN-jRCT2031220623 Japan;Singapore
Yunfeng Cheng
2024 - NCT06479291 China;Hong Kong;Macau
Zhejiang Provincial Hospital of Traditional Chinese Medicine
2022 Phase 1 ChiCTR2200058259 China
Eltrombopag 25 MG
Renata PLC
2025 Phase 1/Phase 2 NCT06531018 Bangladesh
Eltrombopag and dexamethasone
Hospital Universitario Dr. Jose E. Gonzalez
2012 Phase 2 NCT01652599 Mexico
Eltrombopag and romiplastim
Assiut University
2023 - NCT06137105 -
Eltrombopag combining rituximab
Institute of Hematology & Blood Diseases Hospital, China
2020 Phase 4 NCT04518475 China
Eltrombopag olamine
FONDAZIONE PROGETTO EMATOLOGIA
2012 - EUCTR2011-004657-11-IT Italy
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy
Fondazione Progetto Ematologia
2012 Phase 2 NCT01610180 Italy
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-000452-18-ES Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma AG
2018 Phase 2 EUCTR2018-000452-18-GR Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-GB Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-AT Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma GmbH
2020 Phase 2 EUCTR2019-002658-21-DE Germany
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
Eltrombopag olamine, revolade, promacta
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Eltrombopag oral tablets
GlaxoSmithKline
2008 Phase 3 NCT00828750 Japan
Eltrombopag pfos
Institute of Hematology & Blood Diseases Hospital, China
2026 - NCT07476846 -
Eltrombopag plus diacerein
Qilu Hospital of Shandong University
2020 Phase 2 NCT04917679 China
Erythropoietin
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
ESG206
Shanghai Escugen Biotechnology Co., Ltd
2025 Phase 1/Phase 2 NCT06853444 China
Estimation OF serum level OF IL17
Sohag University
2022 - NCT05371743 Egypt
Estimation OF serum level OF IL2
Sohag University
2022 - NCT05371743 Egypt
ETB115
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-000452-18-ES Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma AG
2018 Phase 2 EUCTR2018-000452-18-GR Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-GB Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-AT Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma GmbH
2020 Phase 2 EUCTR2019-002658-21-DE Germany
Ethanolamine
Pingdingshan First People's Hospital
2024 Phase 4 ChiCTR2400090793 China
West China Hospital,Sichuan University
2022 Phase 2 ChiCTR2200065074 China
Fecal microbiome
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Fecal microbiota transplantation
Chinese University of Hong Kong
2019 - NCT04014413 Hong Kong
Filgrastim
Fairview University Medical Center
2000 - NCT00006055 United States
Fludarabine phosphate
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2026 Phase 2 NCT07603557 Denmark;Germany;United Kingdom;United States
Fostamatinib
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2023 - NCT06071520 Spain
Gruppo Italiano Malattie EMatologiche dell'Adulto
2023 - NCT05613296 Italy
Kissei Pharmaceutical Co., Ltd.
2023 - NCT06757257 Japan
2019 Phase 3 JPRN-jRCT2080224916 Japan
Miyakawa Yoshitaka
2026 - JPRN-jRCTs031250344 -
Rigel Pharmaceuticals
2021 - NCT04904276 United States
Fostamatinib disodium
Rigel Pharmaceuticals
2015 Phase 3 NCT02076412 Austria;Bulgaria;Czech Republic;Czechia;Germany;Norway;Poland;Romania;Spain;United States
2014 Phase 3 NCT02077192 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Hungary;Italy;Netherlands;Norway;Poland;Romania;Spain;United Kingdom;United States
2014 Phase 3 NCT02076399 Australia;Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Fostamatinib disodium / R935788
Rigel Pharmaceuticals
2007 Phase 2 NCT00706342 United States
Fostamatinib disodium 100 MG
Rigel Pharmaceuticals
2018 - NCT03363334 -
Fostamatinib disodium 150 MG
Rigel Pharmaceuticals
2018 - NCT03363334 -
Fostamatinib disodium tablets
Rigel Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2013-005454-30-PL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-IT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-ES Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005453-76-ES Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2015 Phase 3 EUCTR2013-005452-15-HU Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-NL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-GB Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-DK Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-CZ Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-BG Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-AT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005453-76-PL Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-CZ Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-BG Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-AT Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005452-15-NL Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-IT Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-GB Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-DK Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
G-CSF
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Gammaplex
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States
Gammaplex, intravenous immunoglobulin
Bio Products Laboratory
2007 Phase 3 NCT00504075 Argentina;India;United States
GL-2045
Gliknik Inc.
2026 Phase 1 NCT07605845 United Kingdom
Global DNA methylation will BE quantified IN THE DNA samples BY colorimetry
Assiut University
2019 - NCT04100876 -
Glycyrrhetinic acid
Shandong University
2019 Phase 4 NCT03998982 China
GMA161
Genzyme, a Sanofi Company
2005 Phase 1 NCT00244257 United States
GNR-069
AO GENERIUM
2022 Phase 3 NCT05492409 Russian Federation
2021 Phase 3 NCT05220878 Russian Federation
GP404141
Geropharm
2023 Phase 3 NCT06497036 Russian Federation
GSK1550188
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2022 Phase 3 EUCTR2021-000006-16-FR France;Italy;Norway;Spain
GlaxoSmithKline Research & Development Limited
2012 - EUCTR2011-000241-21-DE Germany;United Kingdom
2011 - EUCTR2011-000241-21-GB Germany;United Kingdom
H. pylori triple therapy
Federal University of São Paulo
2008 Phase 2/Phase 3 NCT01730352 Brazil
HBM9161 dose A
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China
HBM9161 dose B
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China
HD-DXM
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
Shandong University
2022 Phase 2 NCT05411874 -
Healthy controls
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Herombopag
Jiangsu HengRui Medicine Co., Ltd.
2023 Phase 3 NCT05685420 -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025 - ChiCTR2500097299 China
Yin Jie
2022 Phase 3 NCT05328804 China
Herombopag olamine tablets
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06838949 China
Southern Medical University Southern Hospital
2025 - ChiCTR2500106843 China
Hetrombopag
Fuyang People's hospital
2024 Phase 4 ChiCTR2500095156 China
Jiangsu HengRui Medicine Co., Ltd.
2021 Phase 3 NCT04737850 China
The First Affiliated Hospital of Xi'an Jiaotong University
2024 - ChiCTR2500095505 China
West China Hospital, Sichuan University
2025 - ChiCTR2500096457 China
Wuhan Union Hospital, China
2022 - NCT05333861 China
Hetrombopag 5MG PO QD
Shandong University
2023 Phase 2 NCT05943691 China
Hetrombopag olamine
Jiangsu HengRui Medicine Co., Ltd.
2018 Phase 1 NCT03603132 China
2015 Phase 1 NCT02614846 China
2014 Phase 1 NCT02403440 China
Peking Union Medical College Hospital
2024 Phase 2 NCT06478537 China
Hiberix - polvere E solvente PER soluzione iniettabile PER USO intramuscolare 1 flaconcino DI polvere + 1 siringa preriempita DI solvente DA 0.5 ML
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
High dose dexamethasone
Peking University People's Hospital
2025 Phase 1 NCT07315373 -
High dose dexamethasone pulses
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of
HIGH-dose dexamethasone
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
HenanCancerHospital
2026 - ChiCTR2600120287 China
Shandong University
2023 Phase 2 NCT05943691 China
Subei People's Hospital of Jiangsu province.
2025 Phase 2 ChiCTR2500105480 China
The First Affiliated Hospital of Xi'an Jiaotong University
2024 - ChiCTR2500095505 China
The Second Affiliated Hospital of Guangxi Medical University
2023 Phase 4 ChiCTR2100053604 China
HIGH-dose dexamethasone combined with orelabrutinib
Shandong University
2026 Phase 3 NCT07559331 China
Higher dose OF rituximab
Weill Medical College of Cornell University
2003 Phase 2/Phase 3 NCT00774202 United States
HMPL-523
Hutchison Medipharma Limited
2019 Phase 1 NCT03951623 China
Hutchmed
2024 Phase 1 NCT06291415 Australia;Germany;Norway;Spain;United States
2021 Phase 3 NCT05029635 China
Honey
mamdouh abdulmaksoud abdulrhman
2014 - NCT01462916 Egypt
Huaiqihuang granule
Qidong Gaitianli Medicines Co., Ltd
2017 Phase 4 NCT03201848 China
Human immunoglobulin
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
2020 Phase 3 ChiCTR2300069388 China
LFB BIOTECHNOLOGIES
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Octapharma AG
2007 Phase 3 EUCTR2005-003552-35-FR Austria;Czech Republic;France;Germany
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
ZLB Behring AG
2004 - EUCTR2004-000537-11-DE Germany;Italy
Human immunoglobulin (PH4) FOR intravenous injection
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
2025 Phase 3 NCT07233213 Turkey (Türkiye)
Human immunoglobulin G
Octapharma AG
2006 - EUCTR2005-003552-35-DE Czech Republic;France;Germany
2006 - EUCTR2005-003552-35-AT Austria;Czech Republic;France;Germany
Human immunoglobulin intravenous
Green Cross Corporation
2014 Phase 3 NCT02063789 Korea, Republic of
Human normal immunoglobulin
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2021 Phase 3 EUCTR2021-000292-37-FR France
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands
Human normal immunoglobulin FOR intravenous USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Human normal immunoglobulin FOR intrvenous USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Humax-CD38
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
Hydroxychloroquine
Assiut University
2017 Phase 4 NCT03229746 Egypt
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China
The Second Affiliated Hospital of Kunming Medical University
2023 Phase 4 ChiCTR2300068387 China
Hydroxychloroquine oral tablet
Yunfeng Cheng
2024 - NCT06479317 China;Hong Kong;Macau
2024 - NCT06479304 China;Hong Kong;Macau
2024 - NCT06479291 China;Hong Kong;Macau
Hypersialylated immunoglobulin
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
I10E
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Ianalumab
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001672-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2023 Phase 3 EUCTR2022-001627-32-ES Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-ES Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-RO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-NO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-BG Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-FR Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-BE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-CZ Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-CZ Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharmaceuticals
2026 Phase 2 NCT07421167 United States
2026 Phase 2 NCT07039422 Belgium;China;Czechia;France;Germany;Hungary;Italy;Malaysia;Singapore;Spain;Turkey (Türkiye);United Kingdom
2025 - NCT07244289 -
2023 Phase 2 NCT05885555 Argentina;Australia;China;Czechia;France;Germany;Italy;Malaysia;Poland;South Korea;Spain;Turkey (Türkiye);United Kingdom;United States
2023 Phase 3 NCT05653349 Argentina;Australia;Austria;Belgium;Bulgaria;China;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey (Türkiye);United Kingdom;United States;Vietnam
2023 Phase 3 NCT05653219 Argentina;Australia;Austria;Belgium;China;Czechia;France;Germany;Hungary;India;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;South Korea;Spain;Taiwan;Thailand;Turkey (Türkiye);United Kingdom;United States
Yamauchi Kyosuke
2023 Phase 3 JPRN-jRCT2061220095 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;China;Czech Republic;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Vietnam
2023 Phase 3 JPRN-jRCT2031220623 Japan;Singapore
Ianalumabproduct code: VAY736pharmaceutical form: concentrate FOR solution FOR infusioninn or proposed INN: ianalumabcurrent sponsor code: VAY736concentration unit: MG/ML milligram(S)/millilitreconcentration type: equalconcentration number: 150-pharmaceutical form OF THE placebo: concentrate FOR solution FOR infusionroute OF administration OF THE placebo: intravenous USE
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-FR Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
IG vena 100 ML vial
Kedrion SpA
2013 - EUCTR2013-000961-36-IT Italy
IG vena 50 G/L solution FOR infusion 100 ML vial + infusion SET
Kedrion SpA
2013 Phase 3 EUCTR2013-000961-36-DE Germany;Italy
IGG next generation
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
IGIV3I grifols
Grifols Biologicals Inc.
2008 Phase 3 NCT00511147 Canada;India;Puerto Rico;United States
Instituto Grifols, S.A.
2008 Phase 3 NCT00699140 Russian Federation;Spain;United Kingdom
Igpro10
CSL Behring
2011 Phase 4 NCT01390649 Bulgaria;Poland;Romania;Serbia
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
ZLB Behring AG
2004 - EUCTR2004-000537-11-DE Germany;Italy
Iguratimod
Peking University People's Hospital
2025 Phase 2 NCT07057778 China
2022 Phase 2 NCT05302024 China
2021 Phase 2 NCT05281068 China
Immune globulin intravenous
Baxalta now part of Shire
2002 Phase 3 NCT00157079 United States
Immune globulin intravenous (human), 10% triple virally reduced solution
Baxalta now part of Shire
2003 Phase 2 NCT00162006 Czech Republic;Czechia;Germany;Hungary;Poland
Immunglobulin
Octapharma AG
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Immunoglobulin
CSL Behring
2004 Phase 3 NCT00168038 Germany;Italy;Poland;Russian Federation;Switzerland;Ukraine;United Kingdom
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine
2014 Phase 4 study ChiCTR-IIR-15007523 China
Immunoglobulin G
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland
Octapharma AG
2013 Phase 3 EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Immunoglobulina umana normale
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
Inactivated trivalent influenza vaccine
Neufeld, Ellis J, MD, PhD
2004 - NCT01713855 United States
Inaticabtagene autoleucel injection
Juventas Cell Therapy Ltd.
2025 Phase 1 NCT06826430 China
INCA000585
Incyte Corporation
2025 Phase 2 NCT07104565 Australia;France;Italy;Netherlands;Spain;United Kingdom;United States
Interleukin 2
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT01988506 France
Intravenous immunoglobulin
Fujian Medical University Union Hospital
2022 Phase 4 NCT05520892 China
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Peking University People's Hospital
2023 Phase 2 NCT05634824 -
Intravenous immunoglobulin (ivig), 10% solution FOR infusion
Biopharma Plasma LLC
2022 Phase 3 NCT05422365 Ukraine
Intravenous immunoglobulins
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT04968899 France
Iptacopan
Novartis Farmacéutica, S.A.
2021 Phase 2 EUCTR2021-002039-40-ES Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Novartis Pharmaceuticals
2021 Phase 2 NCT05086744 Germany;Italy;South Korea;Spain;United Kingdom;United States
Iptacopan hydrochloride
Novartis Pharma AG
2021 Phase 2 EUCTR2021-002039-40-DE Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Ivig
Baylor College of Medicine
2019 Phase 3 NCT03939637 United States
Kedrion S.p.A.
2025 Phase 3 NCT07059000 Czechia;Germany;Italy;Romania;Serbia;Spain;Turkey (Türkiye);United States
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Peking University People's Hospital
2023 Phase 2 NCT06577909 China
Ivig infusion
McMaster University
2012 Phase 3 NCT01621204 Canada;Netherlands
IVIG-L
Sanquin
2001 Phase 3 NCT00151840 Poland
JCXH-213
The General Hospital of Western Theater Command
2026 Phase 1 NCT07622329 -
KardéGIC
CHU Toulouse
2021 Phase 4 EUCTR2020-000968-30-FR France
KZR-616
Kezar Life Sciences, Inc.
2020 Phase 2 NCT04039477 Australia;Italy;Poland;Russian Federation;United States
L01fc01
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
Laboratory test
Assiut University
2025 - NCT07059910 -
Lactate dehydrogenase
Sohag University
2025 - NCT07046013 -
Lansoprazole, clarithromycin, amoxycillin
Mahidol University
2006 Phase 4 NCT00467571 Thailand
Levofloxacin-based H. pylori eradication therapy
Al-Mustansiriyah University
2024 - NCT07150286 Iraq
LGD-4665
GlaxoSmithKline
2008 Phase 2 NCT00621894 United States
LIV-gamma SN INJ.
SK Plasma Co., Ltd.
2019 Phase 3 NCT05566990 Korea, Republic of
LNP023
Novartis Farmacéutica, S.A.
2021 Phase 2 EUCTR2021-002039-40-ES Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Novartis Pharma AG
2021 Phase 2 EUCTR2021-002039-40-DE Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
LOW-dose rituximab
Peking University People's Hospital
2025 Phase 2 NCT07057778 China
Luspatercept
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Lusutrombopag
Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
2024 Phase 4 ChiCTR2400080388 China
Shionogi
2010 Phase 2 NCT01129024 United States
Lusutrombopag oral tablet
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06287567 China
Lymphostat B
GlaxoSmithKline Research & Development Limited
2012 - EUCTR2011-000241-21-DE Germany;United Kingdom
2011 - EUCTR2011-000241-21-GB Germany;United Kingdom
M254
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
Mabthera
Assistance Publique - Hôpitaux de Paris
2017 - NCT03154385 France
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
Ostfold Hospital Trust
2006 Phase 3 NCT00344149 Norway
ROCHE
2005 - EUCTR2005-000859-15-IT Italy
Rikshospitalet
2010 Phase 3 EUCTR2005-005918-20-GB France;Sweden;United Kingdom
2008 Phase 3 EUCTR2005-005918-20-FR France;Sweden;United Kingdom
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Sykehuset Østfold, Fredrikstad
2009 Phase 3 EUCTR2005-005918-20-SE France;Sweden;United Kingdom
University Hospital, Toulouse
2009 - NCT00960713 France
MabthéRA
Assistance Publique - Hôpitaux de Paris
2003 Phase 2 NCT00225875 France
Medical standard OF care FOR ITP
Amgen
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Menveo – polvere E soluzione PER soluzione iniettabile
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Methylprednisolone
Fairview University Medical Center
2000 - NCT00006055 United States
Fujian Medical University Second Hospital
2015 Phase 4 study ChiCTR-IPR-15006397 China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
2016 Phase 4 study ChiCTR-IIR-16008994 China
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Methylprednisolone and ivig
The Hospital for Sick Children
2005 Phase 3 NCT00376077 Canada
Metilprednisolone
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Metronidazole
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
Mezagitamab
Shikamura Mitsuhiro
2025 Phase 3 JPRN-jRCT2031250237 Australia;Bulgaria;China;Croatia;Czech Republic;France;Germany;Greece;Hong Kong;Italy;Japan;Netherlands;Norway;Poland;South Korea;Spain;Sweden;Turkey;United Kingdom;United States
2025 Phase 3 JPRN-jRCT2031240667 Australia;China;Hong Kong;Japan;South Korea;Turkey;United Kingdom;United States
Takeda
2025 Phase 3 NCT06948318 Australia;Bulgaria;China;Croatia;Hong Kong;Italy;Japan;Netherlands;Poland;South Korea;Spain;Turkey (Türkiye);United Kingdom;United States
2025 Phase 3 NCT06722235 Australia;Bulgaria;China;Croatia;France;Greece;Hong Kong;Italy;Japan;Netherlands;Norway;Poland;South Korea;Spain;Sweden;Turkey (Türkiye);United Kingdom;United States
Takeda Development Center Americas, Inc. (Takeda)
2022 Phase 2 EUCTR2019-004103-12-GR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-HR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
MINI-pool ivig
Assiut University
2025 - NCT07068126 Egypt
MK-8723
Merck Sharp & Dohme Corp.
2013 Phase 1 NCT01963260 Australia;Georgia;Israel;Moldova, Republic of
Montelukast
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China
Mycophenolate mofetil
The First Affiliated Hospital of Dalian Medical University
2014 - ChiCTR-TRC-14004514 China
University Hospitals Bristol NHS Foundation Trust
2017 Phase 3 EUCTR2017-001171-23-GB United Kingdom
University Hospitals Bristol and Weston NHS Foundation Trust
2017 Phase 3 NCT03156452 United Kingdom
Weill Medical College of Cornell University
2016 Phase 3 NCT02649504 -
Mycophenolate mofetil (MMF) treatment
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
2023 Phase 3 NCT06288932 Pakistan
Nanogam
Hagaziekenhuis
2017 Phase 4 EUCTR2016-004295-22-NL Canada;Netherlands
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands
Neofordex
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT04968899 France
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
Neofordex 40 MG compriméS
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2021 Phase 3 EUCTR2021-000292-37-FR France
Newgam
Octapharma
2011 Phase 3 NCT01349790 Germany
Octapharma AG
2013 Phase 3 EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
NGS
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Nicotinamide adenine dinucleotid/nicotinamide mononucleotide
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 1/Phase 2 NCT06776510 China
Nimenrix
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Ninlaro
Assistance Publique - Hôpitaux de Paris
2019 Phase 2 NCT03965624 France
Nplate
AO GENERIUM
2021 Phase 3 NCT05220878 Russian Federation
Amgen Inc
2015 Phase 3 EUCTR2011-005019-96-PL Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-HU Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-GB Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-CZ Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-BE Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
- - EUCTR2011-005019-96-Outside-EU/EEA Australia;Brazil;Canada;Israel;Mexico;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
- Phase 3 EUCTR2011-005019-96-FR Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
- Phase 3 EUCTR2011-005019-96-ES Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
- - EUCTR2010-018426-39-Outside-EU/EEA Australia;Canada;United States
- - EUCTR2009-016203-32-Outside-EU/EEA Australia;Canada;United States
Geropharm
2023 Phase 3 NCT06497036 Russian Federation
Nplate 500 microgramos polvo para solucióN inyectable
Amgen Inc
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom
NVG-2089
Nuvig Therapeutics, Inc.
2025 Phase 2 NCT07095127 United States
Obinutuzumab
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 2 NCT06094881 China
2023 Phase 2 NCT05995054 China
OM336
Ouro Medicines
2025 Phase 1 NCT07083960 Australia
Orelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
2023 Phase 3 NCT06004856 China
2022 Phase 2 NCT05232149 China
HenanCancerHospital
2026 - ChiCTR2600120287 China
Peking Union Medical College Hospital
2026 Phase 2 NCT07400250 China
Shandong University
2021 Phase 2 NCT05020288 -
Oseltamivir
Fujian Children's Hospital
2023 Phase 2 ChiCTR2300071184 China
Shandong University
2016 Phase 2 NCT01965626 China
St. Michael's Hospital, Toronto
2016 Phase 3 NCT03520049 Canada
Panzyga
Octapharma
2020 Phase 4 NCT03866798 United States
Paracetamolo
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Peripheral blood and bone marrow withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
2023 - NCT05694325 Italy
PF-06755347 intravenous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06755347 subcutaneous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06755347 subcutaneous ITP
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06835375
Pfizer
2022 Phase 2 NCT05070845 Australia;Canada;Czechia;Hungary;Poland;United Kingdom;United States
Pfizer Inc.
2022 Phase 2 EUCTR2021-002897-19-HU Australia;Canada;Czech Republic;Czechia;Hungary;Poland;United States
2022 Phase 2 EUCTR2021-002897-19-CZ Australia;Canada;Czech Republic;Czechia;Hungary;Poland;United States
PG2
PhytoHealth Corporation
2008 Phase 2 NCT00860600 Taiwan
Pirtobrutinib
Eli Lilly and Company
2025 Phase 1/Phase 2 NCT06721013 China;Denmark;France;Italy;Norway;Poland;South Korea;Spain;United Kingdom;United States
Plasma RNA isolation, qpcr analysis OF micro RNA
Sohag University
2022 - NCT05371743 Egypt
Platelet concentrate
Shandong University
2018 Phase 3 NCT03492515 China
PN20
Chongqing Peg-Bio Biopharm Co., Ltd.
2022 Phase 1 NCT06523088 China
PN20 treatment
Chongqing Peg-Bio Biopharm Co., Ltd.
2025 Phase 1 NCT06880081 China
Povetacicept
Alpine Immune Sciences, Inc.
2023 Phase 1/Phase 2 NCT05757570 Australia;Austria;Canada;Germany;Italy;Norway;Spain;Turkey (Türkiye);United Kingdom;United States
Prednisolon
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
Prednisolone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of
Renata PLC
2025 Phase 1/Phase 2 NCT06531018 Bangladesh
University Hospitals Bristol and Weston NHS Foundation Trust
2017 Phase 3 NCT03156452 United Kingdom
Prednisone
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2021 Phase 3 EUCTR2021-000292-37-FR France
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-IIR-17012850 China
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
2013 - ChiCTR-TRC-13003602 China
Fairview University Medical Center
2000 - NCT00006055 United States
Fujian Medical University Union Hospital
2022 Phase 4 NCT05522465 China
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Huizhou Municipal Central Hospital
2022 Phase 4 ChiCTR2100053452 China
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of
Mayo Clinic
2007 Phase 0 NCT00486421 United States
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
New England Research Institutes
2010 Phase 3 NCT00991939 United States
Peking University People's Hospital
2023 Phase 2 NCT06577909 China
2021 Phase 2 NCT05333744 China
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine
2014 Phase 4 study ChiCTR-IIR-15007523 China
Shandong University
2010 Phase 4 NCT01356511 China
Shanghai University of Traditional Chinese Medicine affiliated Yueyang Hospital of traditional Chinese and Western Medicine
2017 - ChiCTR-IOR-16010001 China
Shanxi Province People‘s Hospitall
2025 Phase 0 ChiCTR2500101851 China
Subei People's Hospital of Jiangsu province.
2025 Phase 2 ChiCTR2500105480 China
The Second Affiliated Hospital of Guangxi Medical University
2023 Phase 4 ChiCTR2100053604 China
The Second Affiliated Hospital of Kunming Medical University
2023 Phase 4 ChiCTR2300068387 China
University Hospital, Essen
2002 Phase 3 NCT02334813 -
Zhejiang Provincial Hospital of Traditional Chinese Medicine
2022 Phase 1 ChiCTR2200058259 China
Prednisone (cortancyl®) alone followed BY monitoring and standard OF care
Assistance Publique - Hôpitaux de Paris
2015 Phase 3 NCT02627417 France
Prednisone acetate
Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine
2016 - ChiCTR-INR-16009028 China
2015 - ChiCTR-OCB-15006981 China
Dongzhimen Hospital of Beijing University of Chinese Medicine
2016 Phase 1 study ChiCTR-IIR-16009020 China
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2023 - ChiCTR2300071394 China
Prednisone tablet
Yunfeng Cheng
2024 - NCT06479304 China;Hong Kong;Macau
PRG-1801
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024 Early Phase 1 NCT06519565 China
Privigen
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
PRN1008
Principia Biopharma Inc.
2020 Phase 3 EUCTR2020-002063-60-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, Inc.
2021 Phase 3 EUCTR2020-002063-60-NO Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-HU Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-FR Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-AT Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002063-60-DE Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Türkiye;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-PL Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-GB Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Tanaka Tomoyuki
2022 Phase 3 JPRN-jRCT2051220003 Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Republic of Korea;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
PRN1008 100 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-GB Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
PRN1008 300 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-GB Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
PRN1008 400 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-GB Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Probiotic agent
Shandong University
2017 Phase 2 NCT03033199 China
ProteíNA recombinante estimulante DE LA megacariopoyesis
Amgen Inc.
2007 Phase 2 EUCTR2007-003569-42-ES Spain
Proton pump inhibitor 1 MG/KG/DAY IN 2 divided doses 1 month
Assiut University
2020 Phase 4 NCT03172676 Egypt
PRTX-100
Protalex, Inc.
2015 Phase 1/Phase 2 NCT02566603 France;United Kingdom
2015 Phase 1/Phase 2 NCT02401061 United Kingdom;United States
2007 Phase 1 NCT00571467 Australia;New Zealand
QL0911
Qilu Pharmaceutical Co., Ltd.
2026 Phase 3 NCT07455006 -
2019 Phase 3 NCT05621330 China
QT-019C
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026 Early Phase 1 NCT07416032 China
Quality-OF-life assessment
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Quantitative microbiological test FOR HCV
Assiut University
2019 - NCT04128358 Egypt
R788
Kissei Pharmaceutical Co., Ltd.
2019 Phase 3 NCT04132050 Japan
R935788
Rigel Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2013-005454-30-PL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-IT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-ES Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005453-76-ES Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2015 Phase 3 EUCTR2013-005452-15-HU Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-NL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-GB Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-DK Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-CZ Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-BG Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-AT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005453-76-PL Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-CZ Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-BG Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-AT Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005452-15-NL Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-IT Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-GB Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-DK Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Rapamycin
First Affiliated Hospital of Suzhou Medical College
2011 - NCT01672151 China
RAY121
Chugai Pharmaceutical
2024 Phase 1 NCT06723106 Australia;Austria;Bulgaria;Canada;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey (Türkiye)
2024 Phase 1 NCT06371417 Australia;Austria;Bulgaria;Canada;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey (Türkiye);United States
Recombinant human thrombopoietin
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Institute of Hematology & Blood Diseases Hospital, China
2026 - NCT07476846 -
Peking University People's Hospital
2023 Phase 2 NCT05634824 -
2020 - NCT04214951 China
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine
2014 Phase 4 study ChiCTR-IIR-15007523 China
Shandong University
2018 Phase 3 NCT03492515 China
2014 Phase 3 NCT02139501 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2011 Phase 3 NCT01525836 China
Recombinant human TPO
Peking University People's Hospital
2021 Phase 2 NCT05333744 China
Relovade
GlaxoSmithKline Research and Development Ltd
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
Revolade
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research and Development Limited
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-000452-18-ES Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-GR Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-GB Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-AT Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma GmbH
2020 Phase 2 EUCTR2019-002658-21-DE Germany
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland
Revolade 25 MG FILM-coated tablets
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Revolade 50 MG FILM-coated tablets
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Revolade*28CPR RIV 25MG
FONDAZIONE PROGETTO EMATOLOGIA
2012 - EUCTR2011-004657-11-IT Italy
Revolade, promacta
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
RHIL-11
Ming Hou
2011 - NCT01317966 China
RHO(D) immune globulin
Baylor College of Medicine
2019 Phase 3 NCT03939637 United States
Rhtpo
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-OIC-17012859 China
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China
Institute of Hematology & Blood Diseases Hospital, China
2026 - NCT07476846 -
2022 Phase 4 NCT05583838 China
Nanjing Drum Tower Hospital
2024 Phase 0 ChiCTR2400080036 China
Peking Union Medical College
2011 Phase 3 NCT01805648 China
Peking University People's Hospital
2023 Phase 2 NCT05634824 -
2020 Phase 1 NCT04518878 China
2020 Phase 2 NCT04516837 China
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine
2014 Phase 4 study ChiCTR-IIR-15007523 China
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Shandong University
2015 Phase 3 NCT02391272 China
2014 Phase 3 NCT02270801 China
2014 Phase 3 NCT02203422 China
2014 Phase 3 NCT02139501 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2011 Phase 3 NCT01525836 China
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China
Yin Jie
2022 Phase 3 NCT05328804 China
Rhtpo IN combination with rituximab
Ming Hou
2009 Phase 3 NCT01506414 China
Rilzabrutinib
Obara Kentaro
2025 Phase 3 JPRN-jRCT2031250430 -
Principia Biopharma Inc.
2020 Phase 3 EUCTR2020-002063-60-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, Inc.
2021 Phase 3 EUCTR2020-002063-60-NO Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-HU Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-FR Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-AT Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002063-60-DE Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Türkiye;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-PL Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-GB Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2020 Phase 3 NCT04562766 Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 2 NCT03395210 Australia;Bulgaria;Canada;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Sanofi
2025 Phase 3 NCT07216079 Japan
2025 Phase 3 NCT07007962 Austria;France;Hungary;Italy;Poland;Spain;United States
Tanaka Tomoyuki
2022 Phase 3 JPRN-jRCT2051220003 Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Republic of Korea;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Ripertamab/eltrombopag
Wuhan Union Hospital, China
2025 - NCT06790888 -
Rituxan
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
New York Medical College
2021 Phase 1 NCT04323748 United States
University Hospital, Toulouse
2009 - NCT00960713 France
Rituxan, cyclophosphamide, vincristine, prednisone
Weill Medical College of Cornell University
2003 Phase 2/Phase 3 NCT00774202 United States
Rituximab
Assistance Publique - Hôpitaux de Paris
2017 - NCT03154385 France
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR1900027748 China
Fujian Children's Hospital
2022 Phase 0 ChiCTR2200061828 China
Hamilton Health Sciences Corporation
2006 Phase 2 NCT00372892 Canada
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
2005 Phase 3 NCT00770562 Italy
Hospital Universitario Dr. Jose E. Gonzalez
2015 Phase 2 NCT02834286 Mexico
Institute of Hematology & Blood Diseases Hospital, China
2026 Phase 2 NCT07362238 China
2026 Phase 2 NCT07362199 China
2026 Phase 2 NCT07297563 China
2026 Phase 2 NCT07234019 China
2012 - NCT01719692 China
Keio University School of Medicine , Yoshitaka miyakawa
2011 Phase 3 JPRN-jRCT1091220070 Japan
Mayo Clinic
2007 Phase 0 NCT00486421 United States
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
Neufeld, Ellis J, MD, PhD
2003 Phase 1/Phase 2 NCT01713738 United States
Ostfold Hospital Trust
2025 Phase 3 NCT07051915 -
2016 Phase 3 NCT03010202 Norway
2006 Phase 3 NCT00344149 Norway
Peking University People's Hospital
2017 Phase 2 NCT03304288 China
ROCHE
2005 - EUCTR2005-000859-15-IT Italy
Rikshospitalet
2008 Phase 3 EUCTR2005-005918-20-FR France;Sweden;United Kingdom
Shandong University
2018 Phase 3 NCT03443570 China
2014 Phase 3 NCT02137681 China
2012 Phase 3 NCT01734057 China
2011 Phase 3 NCT01525836 China
2010 Phase 4 NCT03258866 China
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Sykehuset Østfold, Fredrikstad
2009 Phase 3 EUCTR2005-005918-20-SE France;Sweden;United Kingdom
The First Affiliated Hospital of Soochow University
2025 - NCT07206823 China
The Second Affiliated Hospital of Kunming Medical University
2022 Phase 1 ChiCTR2200057058 China
2021 Phase 4 ChiCTR2100051890 China
2020 Phase 4 ChiCTR2000030603 China
University Hospital, Toulouse
2009 - NCT00960713 France
University of Alabama at Birmingham
2000 Phase 2 NCT00005652 United States
Weill Medical College of Cornell University
2016 Phase 3 NCT02649504 -
2004 Phase 2 NCT00161564 United States
Rituximab and dexamethasone
Hospital Universitario Dr. Jose E. Gonzalez
2010 Phase 2 NCT01107951 Mexico
Rituximab plus methylprednisolone
Peking University People's Hospital
2016 Phase 2 NCT02757196 -
Rocaltrol
Shandong University
2020 Phase 4 NCT04094805 China
Romiplostim
Amgen
2014 Phase 3 NCT02279173 Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Hungary;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2012 Phase 3 NCT01444417 Australia;Canada;United States
2010 Phase 2 NCT01143038 Australia;Czech Republic;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
2009 Phase 3 NCT01071954 Australia;Canada;Spain;United States
2009 Phase 4 NCT00907478 Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;United States
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2005 Phase 3 NCT00508820 Australia;Austria;Belgium;Canada;Czech Republic;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom;United States
2004 Phase 3 NCT00116688 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2002 Phase 1/Phase 2 NCT00117143 -
2002 Phase 2 NCT00111475 -
Amgen Inc
2015 Phase 3 EUCTR2011-005019-96-PL Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-HU Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-GB Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-CZ Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-BE Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
- - EUCTR2011-005019-96-Outside-EU/EEA Australia;Brazil;Canada;Israel;Mexico;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
- Phase 3 EUCTR2011-005019-96-FR Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
- Phase 3 EUCTR2011-005019-96-ES Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
- - EUCTR2010-018426-39-Outside-EU/EEA Australia;Canada;United States
- - EUCTR2009-016203-32-Outside-EU/EEA Australia;Canada;United States
Chinese Academy of Medical Science Hematology Hospital
2015 Phase 1+Phase 2 ChiCTR-OPC-15007012 China
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
GlaxoSmithKline
2010 - NCT01439321 -
2009 - NCT01236014 -
Kyowa Kirin China Pharmaceutical Co., Ltd.
2015 Phase 1/Phase 2 NCT02868060 China
Samsung Medical Center
2015 Phase 2 NCT02338414 -
Shanxi Province People‘s Hospitall
2025 Phase 0 ChiCTR2500101851 China
The First Affiliated Hospital of Soochow University
2026 - NCT07612319 China
University Hospital, Basel, Switzerland
2016 Phase 4 NCT02760251 Switzerland
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Romiplostim and danazol
Seoul National University Hospital
2020 Phase 2 NCT04289207 -
Romiplostim N01
Peking Union Medical College Hospital
2026 Phase 2 NCT07400250 China
Qilu Hospital of Shandong University
2024 Phase 4 ChiCTR2400091685 China
The First Affiliated Hospital of Soochow University
2025 - NCT07206823 China
Romiplostim N01 combined with dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06992128 China
Romiplostim plus dexamethasone
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022 Phase 3 NCT05325593 Italy;Spain;United Kingdom
Romiplostin
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 - NCT02298075 Italy
Subei People's Hospital of Jiangsu province.
2025 Phase 2 ChiCTR2500105480 China
Ropivacaine
Huai'an First People's Hospital
2025 Phase 2 ChiCTR2500104776 China
Rozanolixizumab
Sugihara Kazuhiro
2021 Phase 3 JPRN-jRCT2031210245 Austria;Belgium;Bulgaria;Canada;China;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea;Poland;Republic of Moldova;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
UCB Biopharma SRL
2021 Phase 3 NCT04596995 China;Georgia;Germany;Hungary;Italy;Japan;Moldova, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04224688 Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Italy;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04200456 Austria;Belgium;Bulgaria;Croatia;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-jRCT2080225255 Asia except Japan;Europe;Japan;North America
Rozanolixizumabproduct code: UCB7665pharmaceutical form: solution FOR infusioninn or proposed INN: rozanolixizumabcas number: 1584645-37-3current sponsor code: UCB7665concentration unit: MG/ML milligram(S)/millilitreconcentration type: equalconcentration number: 140-pharmaceutical form OF THE placebo: solution FOR infusionroute OF administration OF THE placebo: subcutaneous USE
UCB Biopharma SRL
2020 Phase 3 EUCTR2019-000884-26-FR Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
S-888711
SHIONOGI USA, INC
2010 - EUCTR2009-017942-30-IT France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-016950-42-IT France;Hungary;Italy;United Kingdom
Shionogi
2010 Phase 2 NCT01054443 United States
Shionogi USA, Inc.
2010 - EUCTR2009-017942-30-HU France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-017942-30-GB France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-017942-30-FR France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-017942-30-DE France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-016950-42-HU France;Hungary;Italy;United Kingdom
2010 - EUCTR2009-016950-42-GB France;Hungary;Italy;United Kingdom
2010 Phase 2 EUCTR2009-016950-42-FR France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-016950-42-DE France;Germany;Hungary;Italy;United Kingdom
SAR444671
Obara Kentaro
2025 Phase 3 JPRN-jRCT2031250430 -
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
SB-497115
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
GlaxoSmithKline Research and Development Limited
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
SB-497115-GR
GLAXO SMITHKLINE
2006 - EUCTR2004-000367-98-IT Denmark;Estonia;Germany;Ireland;Italy;Latvia;Spain;Sweden
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline Research and Development Limited
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
SB-497115-GR 12.5MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB-497115-GR 25MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB-497115-GR 50 MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB497115
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
2005 Phase 2 NCT00102739 Australia;Brazil;Canada;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2004-000367-98-DK Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-SE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-LV Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-IE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 Phase 2 EUCTR2004-000367-98-GB Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 Phase 2 EUCTR2004-000367-98-ES Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-EE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-DE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
GlaxoSmithKline S.A.
2006 - EUCTR2006-000471-14-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline, S.A.
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
Search FOR thyroid disorders
Assiut University
2025 - NCT07059910 -
Second line ITP agents
Boston Children's Hospital
2013 - NCT01971684 Canada;United States
Serological assay FOR blood born viral hepatitis
Assiut University
2019 - NCT04128358 Egypt
Serum IL10 BY elisa
Sohag University
2022 - NCT05410249 Egypt
Serum interleukin 10 level
Sohag University
2023 - NCT05835050 Egypt
SHR-2173 injection
Guangdong Hengrui Pharmaceutical Co., Ltd
2025 Phase 1 NCT07206758 China
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States
Chinese SLE Treatment And Research Group
2026 Phase 2/Phase 3 NCT07657793 China
Department of Hematology, Xiniao Hospital
2017 - ChiCTR-ONC-17012126 China
The Second Affiliated Hospital of Army Military Medical University
2022 Phase 4 ChiCTR2100052913 China
Sitagliptin
Peking University People's Hospital
2021 Phase 2 NCT05353673 China
SKI-O-703
Oscotec Inc.
2021 Phase 2 EUCTR2018-003329-26-PL Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 NCT04056195 Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 EUCTR2018-003329-26-GR Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 EUCTR2018-003329-26-ES Greece;Korea, Republic of;Poland;Spain;United States
SM101
SuppreMol GmbH
2010 Phase 1;Phase 2 EUCTR2009-014842-28-BE Belgium;Germany;Poland
SM101 20MG/ML
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine
SM101 5MG/ML
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine
SNP -3279 A/C OF FOXP3
Sohag University
2022 - NCT05410249 Egypt
SNP-924 A/G OF FOXP3
Sohag University
2022 - NCT05410249 Egypt
Spleen sample
Centre Hospitalier Universitaire Dijon
2014 - NCT02821572 France
Spleen samples
Centre Hospitalier Universitaire Dijon
2011 - NCT02042560 France
Standard OF care
Eisai Inc.
2012 Phase 3 NCT01438840 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 NCT01433978 United States
Standard therapy (without eltrombopag): HD-DXM
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland
Steroid and eltrombopage
Assiut University
2025 - NCT07059910 -
Steroids
Baylor College of Medicine
2019 Phase 3 NCT03939637 United States
Safaa AA Khaled
2019 - NCT04113915 -
STSA-1301 subcutaneous injection
Jiangsu BioJeTay Biotechnology Co., Ltd.
2025 Phase 1/Phase 2 NCT06929299 China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
2023 Phase 1 NCT06148389 China
SYM001
Symphogen A/S
2010 Phase 2 EUCTR2007-006081-15-GB Belgium;Germany;India;Israel;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2010 Phase 2 EUCTR2007-006081-15-BE Belgium;Germany;Spain;United Kingdom
2008 Phase 2 NCT00718692 Belgium;Germany;India;Israel;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2008 - EUCTR2007-006081-15-ES Belgium;Germany;Spain;United Kingdom
2008 - EUCTR2007-006081-15-DE Belgium;Germany;Spain;United Kingdom
T cell injection targeting CD19 chimeric antigen receptor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
2024 Early Phase 1 NCT06417398 -
Tacrolimus
Peking University People's Hospital
2021 Phase 2 NCT04747080 China
TAK-079
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Shikamura Mitsuhiro
2025 Phase 3 JPRN-jRCT2031250237 Australia;Bulgaria;China;Croatia;Czech Republic;France;Germany;Greece;Hong Kong;Italy;Japan;Netherlands;Norway;Poland;South Korea;Spain;Sweden;Turkey;United Kingdom;United States
Takeda
2020 Phase 2 NCT04278924 Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Takeda Development Center Americas, Inc. (Takeda)
2022 Phase 2 EUCTR2019-004103-12-GR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-HR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Telitacicept
The Second Affiliated Hospital of Kunming Medical University
2021 Phase 4 ChiCTR2100051890 China
Terbutaline
Peking University People's Hospital
2020 Phase 2 NCT04481282 China
Teriflunomide
Peking University People's Hospital
2025 Phase 2 NCT07065968 China
2023 Phase 2 NCT06190145 China
2023 Phase 2 NCT06176911 China
2023 Phase 2 NCT06176235 China
Thalidomide
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-OIC-17012860 China
2017 Phase 2 study ChiCTR-OIC-17012859 China
2017 Phase 2 study ChiCTR-IIR-17012850 China
Shandong University
2013 Phase 2 NCT01976195 China
THE best available therapy
Institute of Hematology & Blood Diseases Hospital, China
2021 Phase 2/Phase 3 NCT04915482 China
Thrombopoietin
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Thrombopoietin receptor agonist
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Novartis Pharmaceuticals
2026 Phase 2 NCT07421167 United States
TPO
Peking University People's Hospital
2020 - NCT04214951 China
Shenyang Sunshine Pharmaceutical Co., LTD.
2016 Phase 4 NCT04089267 China
TPO-RA
Institute of Hematology & Blood Diseases Hospital, China
2021 - NCT04890041 China
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
Novartis Pharmaceuticals
2026 Phase 2 NCT07421167 United States
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025 - ChiCTR2500097299 China
TPO-RA discontinuation
Assistance Publique - Hôpitaux de Paris
2017 Phase 4 NCT03119974 France
TPO-RAS combining ANTI-CD 20 monoclonal antibody
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 4 NCT05718856 China
TQB3473 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025 Phase 2 NCT07083739 China
2025 Phase 3 NCT06900920 China
Treatment : H. pylori eradication
Seoul National University Hospital
2017 Phase 3 NCT03177629 Korea, Republic of
Tretinoin
The First Affiliated Hospital of Xinjiang Medical University
2025 - ChiCTR2500099739 China
Triple therapy
Safaa AA Khaled
2019 - NCT04113915 -
Tysabri
Sahlgrenska University Hospital
2009 Phase 1;Phase 2 EUCTR2008-005871-92-SE Sweden
UCB7665
UCB Biopharma S.P.R.L.
2016 Phase 2 NCT02718716 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
UCB Biopharma SPRL
2017 Phase 2 EUCTR2015-003984-12-LT Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2017 Phase 2 EUCTR2015-003984-12-BG Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-PL Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-ES Australia;Belgium;Bulgaria;Czech Republic;France;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-DE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-BE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
UCB Biopharma SRL
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2016 Phase 2 EUCTR2015-003984-12-IT Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
Universal STAR-T cell
Jian Zhu
2026 Phase 1 NCT07599280 China
Upadacitinib
Peking University People's Hospital
2025 Phase 2 NCT07064889 China
Urine sample
University Hospital, Bordeaux
2019 - NCT04005638 France
Vaccino contro IL memingococco DI gruppo B
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Vaccino haemophilus influenzae B coniugato CON tossoidetetanico
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
VAY736
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001672-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2023 Phase 3 EUCTR2022-001627-32-ES Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-ES Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-RO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-NO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-BG Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-FR Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-BE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-CZ Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-CZ Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Veltuzumab
Gilead Sciences
2007 Phase 1/Phase 2 NCT00547066 United States
Vinblastine
Nanjing Drum Tower Hospital
2024 Phase 0 ChiCTR2400080036 China
Vincristine
Assiut University
2017 Phase 4 NCT03229746 Egypt
VIT D
Mansoura University
2023 Early Phase 1 NCT06073925 -
Vonoprazan
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
Water
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
YTS109 cell injection
China Immunotech (Beijing) Biotechnology Co., Ltd.
2025 Phase 1 NCT06943937 China
Zanubrutinib
He'nan Cancer Hospital
2022 Phase 4 ChiCTR2200060868 China
Institute of Hematology & Blood Diseases Hospital, China
2022 Phase 2 NCT05214391 China
Peking University People's Hospital
2022 Phase 2 NCT05369377 China
2022 Phase 2 NCT05369364 -
2022 Phase 2 NCT05279872 China
The First Affiliated Hospital, College of Medicine, Zhejiang University
2023 Phase 2 ChiCTR2400081061 China
The Second Affiliated Hospital of Kunming Medical University
2022 Phase 1 ChiCTR2200057058 China
Zanubrutinib 160MG/D
Peking University People's Hospital
2025 Phase 1 NCT07315373 -
Zanubrutinib 240MG/D
Peking University People's Hospital
2025 Phase 1 NCT07315373 -
Zanubrutinib 80MG/D
Peking University People's Hospital
2025 Phase 1 NCT07315373 -
Zuberitamab
Union hospital tongji medical college huazhong university of science and technology
2021 Phase 2 ChiCTR2100050513 China
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501 cyclodextrin oral solution
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501 lipid-based oral
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501-P21% powder
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
5% (5G/100 ML) intravenous immunoglobin
On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.
2025 Phase 3 NCT06962631 Brazil
Acetaminophen and diphenhydramine only product
Baylor College of Medicine
2021 Phase 1 NCT04741139 United States
Acetominophen
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Acetylcysteine
Peking University People's Hospital
2019 Phase 2 NCT04368598 China
2018 Phase 1/Phase 2 NCT03460808 China
Acide ACétylsalicylique
CHU Toulouse
2021 Phase 4 EUCTR2020-000968-30-FR France
ACT-HIB polvere E solvente PER soluzione iniettabile IN siringa preriempita 0,5 ML
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
AKR-501, YM-477
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
Alemtuzumab, rituximab
Hospital Universitario Dr. Jose E. Gonzalez
2008 Phase 2/Phase 3 NCT00749112 Mexico
ALL trans retinoic acid
Peking University People's Hospital
2020 Phase 2 NCT04618328 China
ALL-trans retinoic acid
Peking University People's Hospital
2026 Phase 3 NCT07597395 China
2017 Phase 2 NCT03304288 China
2012 Phase 2 NCT01667263 China
ALL-trans-retinoid acid
First Affiliated Hospital of Suzhou Medical College
2011 - NCT01668615 China
AMG 531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
Amgen
2007 Phase 3 NCT00603642 Japan
2007 Phase 1/Phase 2 NCT00515203 Australia;Canada;Spain;United States
2005 Phase 3 NCT00102336 United States
2005 Phase 3 NCT00102323 France;Netherlands;Spain;United States
Amgen Inc
2015 Phase 3 EUCTR2011-005019-96-PL Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-HU Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-GB Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-CZ Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-BE Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2005 Phase 3 EUCTR2004-000174-31-GB Spain;United Kingdom
2005 - EUCTR2004-000174-31-ES Spain;United Kingdom
2005 Phase 3 EUCTR2004-000173-65-GB Spain;United Kingdom
2005 - EUCTR2004-000173-65-ES Spain;United Kingdom
- - EUCTR2011-005019-96-Outside-EU/EEA Australia;Brazil;Canada;Israel;Mexico;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
- Phase 3 EUCTR2011-005019-96-FR Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
- Phase 3 EUCTR2011-005019-96-ES Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2007-000638-37-IE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 Phase 3 EUCTR2004-000172-13-GB Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-DE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-CZ Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-BE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-AT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2007 Phase 2 EUCTR2007-003569-42-ES Spain
2007 - EUCTR2006-003700-18-PT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
- - EUCTR2010-018426-39-Outside-EU/EEA Australia;Canada;United States
- - EUCTR2009-016203-32-Outside-EU/EEA Australia;Canada;United States
AMG531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2004-000172-13-IT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
Amifostine
The First Affiliated Hospital of Dalian Medical University
2014 - ChiCTR-TRC-14004514 China
Aminophylline
Department of Hematology, The First Affiliated Hospital of Soochow University
2017 - ChiCTR-ONC-17013230 China
Amoxicillin
Assiut University
2020 Phase 4 NCT03172676 Egypt
Amoxicillin hydrate
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
ANTI-CD20 monoclonal antibody and THE BTK inhibitor
Qi deng
2026 Phase 1 NCT07574073 -
ANTI-CD38 antibody injection
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 2 NCT06168851 China
ANTI-CD40L
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
ANTI-CD40ldab
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
ANTI-D
University of Aarhus
2004 Phase 2 NCT00128882 Denmark
ANTI-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006055 United States
Aprednisolon
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
ARGX-113
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
Gandini Domenica
2022 Phase 3 JPRN-jRCT2071210087 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Latvia;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
argenx
2017 Phase 2 NCT03102593 Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
Aspirin
Peking Union Medical College Hospital
2024 Phase 2 NCT06478537 China
University Hospital, Toulouse
2023 Phase 2 NCT04912505 France
Atorvastatin
Peking University People's Hospital
2018 Phase 1/Phase 2 NCT03460808 China
Atorvastatin 10MG
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China
Atorvastatin 20MG
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China
Atorvastatin 40 MG oral tablet + N-acetylcysteine 400 MG oral tablet
Hospital Civil de Guadalajara
2018 Early Phase 1 NCT05551624 Mexico
Atra
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Peking University People's Hospital
2026 Phase 3 NCT07597395 China
2020 Phase 2 NCT04217148 China
Shandong University
2013 Phase 3 NCT01882127 China
Autologous ANTI-bcma chimeric antigen receptor T cells
The First Affiliated Hospital of Soochow University
2022 Phase 2 NCT05315778 China
Autologous peripheral blood stem cell transplantation
Fairview University Medical Center
2000 - NCT00006055 United States
Avatrombopag
Eisai Inc.
2012 Phase 3 NCT01438840 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 NCT01433978 United States
Eisai Limited
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
Fuyang People's hospital
2024 Phase 4 ChiCTR2500095156 China
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06281327 China
2021 Phase 2 NCT04993885 China
Ostfold Hospital Trust
2025 Phase 3 NCT07051915 -
Shandong University
2021 - NCT04949009 China
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
Shimizu Yasuko
2022 Phase 3 JPRN-jRCT2031220005 -
Sobi, Inc.
2021 Phase 3 NCT04516967 France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Swedish Orphan Biovitrum
2022 - NCT04943042 Croatia;Czechia;Germany;Ireland;Italy;Netherlands;Norway;Spain;Switzerland;United Kingdom
Avatrombopag 20 MG oral tablet
Al-Mustansiriyah University
2025 Phase 4 NCT07133659 Iraq
Dova Pharmaceuticals
2021 Phase 3 NCT05046327 -
Avatrombopag maleate
Dova Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Sobi, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE France;Germany;Hungary;Poland;Russian Federation;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Avatrombopag oral tablet
Sobi, Inc.
2022 Phase 3 NCT05369208 Japan
2021 Phase 4 NCT04638829 United States
Avatrombopag tablets
Eisai Inc.
2007 Phase 2 NCT00625443 United States
2007 Phase 2 NCT00441090 United States
Avatrombopag+ALL trans retinoic acid
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2/Phase 3 NCT07278908 -
Azathioprine
Assiut University
2017 Phase 4 NCT03229746 Egypt
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China
B02bx05
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Baricitinib
Peking University People's Hospital
2022 Phase 2 NCT05446831 China
Baricitinib 2 MG
Peking University People's Hospital
2023 Phase 2 NCT05932524 China
2023 Phase 2 NCT05852847 China
BCMA-CD19 ccar T cells
iCell Gene Therapeutics
2024 Phase 1 NCT06787989 China
Belantamab mafodotin
Hellenic Society of Hematology
2025 Phase 2 NCT07019545 Greece
Belimumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2022 Phase 3 EUCTR2021-000006-16-FR France;Italy;Norway;Spain
Assistance Publique - Hôpitaux de Paris
2017 - NCT03154385 France
GlaxoSmithKline
2013 Phase 2 NCT01440361 Germany;United Kingdom
GlaxoSmithKline Research & Development Limited
2012 - EUCTR2011-000241-21-DE Germany;United Kingdom
2011 - EUCTR2011-000241-21-GB Germany;United Kingdom
The Second Affiliated Hospital of Kunming Medical University
2022 - ChiCTR2200058433 China
Benlysta
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2022 Phase 3 EUCTR2021-000006-16-FR France;Italy;Norway;Spain
Assistance Publique - Hôpitaux de Paris
2017 - NCT03154385 France
GlaxoSmithKline Research & Development Limited
2012 - EUCTR2011-000241-21-DE Germany;United Kingdom
2011 - EUCTR2011-000241-21-GB Germany;United Kingdom
Bexsero – sospensione iniettabile – siringa preriempita
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
BI 655064
Boehringer Ingelheim
2013 Phase 1 NCT02009761 United States
Biological tests
University Hospital, Brest
2015 - NCT02891109 France
Biological: M254
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
BIVV009 6.5 grams
Bioverativ, a Sanofi company
2017 Phase 1 NCT03275454 Germany;United Kingdom;United States
BIVV009 7.5 grams
Bioverativ, a Sanofi company
2017 Phase 1 NCT03275454 Germany;United Kingdom;United States
BIVV020
Bioverativ, a Sanofi company
2021 Phase 2 NCT04669600 Czechia;Germany;Netherlands;Spain;United Kingdom;United States
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004162-18-NL Austria;Belgium;Czech Republic;Czechia;Germany;Netherlands;Spain;United Kingdom
2021 Phase 2 EUCTR2020-004162-18-ES Austria;Belgium;Czech Republic;Czechia;Germany;Netherlands;Spain;United Kingdom
2021 Phase 2 EUCTR2020-004162-18-DE Austria;Belgium;Czech Republic;Czechia;Germany;Netherlands;Spain;United Kingdom
2021 Phase 2 EUCTR2020-004162-18-CZ Austria;Belgium;Czech Republic;Czechia;Germany;Netherlands;Spain;United Kingdom
Blisibimod
Anthera Pharmaceuticals
2015 Phase 2/Phase 3 NCT01609452 -
Blood draw FOR future biomarker analysis
Genzyme, a Sanofi Company
2019 Phase 4 NCT03784898 United States
Blood sample
Assistance Publique - Hôpitaux de Paris
2012 - NCT02287649 France
Centre Hospitalier Universitaire Dijon
2014 - NCT02821572 France
University Hospital, Bordeaux
2019 - NCT04005638 France
Blood samples
Centre Hospitalier Universitaire Dijon
2011 - NCT02042560 France
University Hospital, Bordeaux
2021 - NCT04800458 France
2009 - NCT04071496 -
BMS-986004
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
BMS-986004 1500 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 225 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 675 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 75 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986353
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2026 Phase 2 NCT07603557 Denmark;Germany;United Kingdom;United States
BMS-986413
Imperial College Healthcare NHS Trust
2021 Phase 2 NCT05393999 United Kingdom
BMS-986414
Imperial College Healthcare NHS Trust
2021 Phase 2 NCT05393999 United Kingdom
Bortezomib
Fujian Children's Hospital
2022 Phase 0 ChiCTR2200061828 China
Seoul National University Hospital
2023 Phase 2 NCT05599880 South Korea
Shandong University
2018 Phase 3 NCT03443570 China
2017 Phase 2 NCT03013114 China
BT595
Biotest
2016 Phase 3 NCT02859909 Bulgaria;Czechia;Germany;Hungary;Serbia;Spain
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
BU zhong YI QI tang, ZHI XUE tang, chuan XIN lian kang YAN pian MOD, tian wang BU XIN DAN
Hadassah Medical Organization
2011 Phase 2/Phase 3 NCT01226524 Israel
Budoprutug
Climb Bio, Inc.
2025 Phase 1/Phase 2 NCT07043946 Bulgaria;Greece;Serbia;Spain;Ukraine
Bélimumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2022 Phase 3 EUCTR2021-000006-16-FR France;Italy;Norway;Spain
Caffeic acid
Shandong University
2012 Phase 3 NCT02351622 China
Caffeic acid tablets
Shandong University
2015 Phase 4 NCT02556814 China
Caplacizumab
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
CAR-T cells
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
2024 Phase 1/Phase 2 NCT06352281 China
Shanghai Cell Therapy Group Co.,Ltd
2025 Early Phase 1 NCT07174843 China
Cart infusion
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026 Early Phase 1 NCT07441525 China
CC312
CytoCares Inc
2024 Early Phase 1 NCT06888960 China
CD19 and BCMA-targeted allogeneic CAR-T cells
The First Affiliated Hospital of Soochow University
2025 Phase 1 NCT07072247 China
CD19 UCAR-T cells
Institute of Hematology & Blood Diseases Hospital, China
2026 - NCT07212322 China
CD4-IGG
Genentech, Inc.
1997 Phase 1 NCT00002250 United States
Cevidoplenib
Oscotec Inc.
2021 Phase 2 EUCTR2018-003329-26-PL Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 EUCTR2018-003329-26-GR Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 EUCTR2018-003329-26-ES Greece;Korea, Republic of;Poland;Spain;United States
Chidamide
Shandong University
2022 Phase 2 NCT05411874 -
2021 Phase 1/Phase 2 NCT03838354 China
CID-103
CASI Pharmaceuticals, Inc.
2025 Phase 1/Phase 2 NCT07017725 China
Clarithromycin
Assiut University
2020 Phase 4 NCT03172676 Egypt
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
CM313 injection
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06199089 China
2023 Phase 2 NCT05694767 China
Keymed Biosciences Co.Ltd
2024 Phase 2 NCT06594146 China
CM336 injection
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06799611 China
Keymed Biosciences Co.Ltd
2025 Phase 1/Phase 2 NCT07175493 China
CNCT19 cell injection
Peking Union Medical College Hospital
2023 Early Phase 1 NCT05930314 China
Collection OF biological samples
University Hospital, Bordeaux
2011 Phase 3 NCT04070599 France
Combination OF rituximab with subcutaneous belimumab
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT05338190 France
Combined USE OF TPO-RAS with LOW-dose ANTI-CD20 antibody
Institute of Hematology & Blood Diseases Hospital, China
2021 Phase 2/Phase 3 NCT04915482 China
Complete blood picture
Assiut University
2017 - NCT03244410 -
Conventional
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt
Subei People's Hospital of Jiangsu province.
2025 Phase 2 ChiCTR2500105480 China
Corticosteriod FOR treated patients
Assiut University
2023 - NCT04482777 -
Corticosteroids
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria
Novartis Pharmaceuticals
2023 Phase 3 NCT05653349 Argentina;Australia;Austria;Belgium;Bulgaria;China;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey (Türkiye);United Kingdom;United States;Vietnam
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China
Corticosteroids combined with immunoglobulin and romiplostim
Wuhan Union Hospital, China
2024 Phase 2 NCT06686927 China
CTX112
CRISPR Therapeutics AG
2026 Phase 1/Phase 2 NCT07549698 Spain;United States
Cyclophosphamide
Fairview University Medical Center
2000 - NCT00006055 United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2026 Phase 2 NCT07603557 Denmark;Germany;United Kingdom;United States
Cyclosporin A
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Shandong University
2014 Phase 3 NCT02203422 China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China
Cyclosporine
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-OIC-17012860 China
Fairview University Medical Center
2000 - NCT00006055 United States
The First Affiliated Hospital of Zhejiang Chinese Medical University
2026 - ChiCTR2600125760 China
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China
The Second Affiliated Hospital of Kunming Medical University
2022 - ChiCTR2200058433 China
2020 Phase 4 ChiCTR2000030603 China
Zhejiang Provincial Hospital of Traditional Chinese Medicine
2022 Phase 0 ChiCTR2200062120 China
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China
Cytokine essays
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Daclizumab
National Institutes of Health Clinical Center (CC)
2002 Phase 2 NCT00049725 United States
Danazol
Peking University People's Hospital
2023 Phase 2 NCT06176911 China
2023 Phase 2 NCT05852847 China
2021 Phase 2 NCT05353673 China
2021 Phase 2 NCT05281068 China
2020 Phase 2 NCT04481282 China
2018 Phase 1/Phase 2 NCT03460808 China
2012 Phase 2 NCT01667263 China
Peking University People's Hospital, Peking University Institute of Hematology
2012 - ChiCTR-TRC-12002424 China
Second Affiliated Hospital of Dalian Medical University
2018 - ChiCTR1800016177 China
Dapsone
Assistance Publique - Hôpitaux de Paris
2015 Phase 3 NCT02627417 France
Daratumumab
Institute of Hematology & Blood Diseases Hospital, China
2026 Phase 2 NCT07362238 China
2026 Phase 2 NCT07362199 China
2026 Phase 2 NCT07297563 China
2026 Phase 2 NCT07234019 China
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
the First Affiliated Hospital of University of Science and Technology of China
2024 Phase 0 ChiCTR2400091558 China
Daratumumab injection
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT07063199 China
2024 Phase 2 NCT06838962 China
2022 Phase 2 NCT05562882 China
Ostfold Hospital Trust
2021 Phase 2 NCT04703621 Denmark;France;Norway
Darzalex
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
Decitabine
Shandong University
2018 Phase 3 NCT03252457 China
2015 Phase 2 NCT01568333 China
Desametasone 40MG
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
DEX combined with RTX, CSA and ivig
Shandong University
2016 Phase 3 NCT02834468 China
Dexamethasone
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-IIR-17012850 China
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
Fujian Medical University Union Hospital
2022 Phase 4 NCT05522465 China
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Hellenic Society of Hematology
2025 Phase 2 NCT07019545 Greece
Hoffmann-La Roche
2005 Phase 3 NCT00770562 Italy
Hospital Universitario Dr. Jose E. Gonzalez
2015 Phase 2 NCT02834286 Mexico
Inner Mongolia International Mongolian Medical Hospital
2023 Phase 1 ChiCTR2300074376 China
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
Novartis Pharma GmbH
2020 Phase 2 EUCTR2019-002658-21-DE Germany
Novartis Pharmaceuticals
2020 Phase 2 NCT04346654 Germany
Ostfold Hospital Trust
2016 Phase 3 NCT03010202 Norway
Peking University People's Hospital
2025 Phase 2 NCT07065968 China
2025 Phase 2 NCT07064889 China
2023 Phase 2 NCT06176235 China
2023 Phase 2 NCT05932524 China
2022 Phase 2 NCT05369364 -
2021 Phase 2 NCT04747080 China
2020 Phase 2 NCT04217148 China
2019 Phase 2 NCT04368598 China
2016 Phase 2/Phase 3 NCT02751593 -
Shandong University
2021 Phase 2 NCT05023915 China
2021 Phase 2/Phase 3 NCT03692754 China
2020 - NCT04320225 -
2020 Phase 4 NCT04094805 China
2019 Phase 4 NCT03998982 China
2018 Phase 3 NCT03252457 China
2017 Phase 2 NCT03033199 China
2016 Phase 2 NCT01965626 China
2015 Phase 4 NCT02642380 China
2015 Phase 4 NCT02556814 China
2014 Phase 2 NCT02153060 China
2013 Phase 2 NCT01976195 China
2013 Phase 3 NCT01882127 China
2012 Phase 3 NCT02351622 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2010 Phase 4 NCT01356511 China
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
The Second Affiliated Hospital of Army Military Medical University
2022 Phase 4 ChiCTR2100052913 China
University Hospital, Essen
2002 Phase 3 NCT02334813 -
University Hospital, Macau
2015 - ChiCTR1900021211 China
Weill Medical College of Cornell University
2016 Phase 3 NCT02649504 -
Zhejiang Provincial Hospital of Traditional Chinese Medicine
2022 Phase 1 ChiCTR2200058259 China
Dexamethasone abcur
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Dexamethasone acetate
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2021 Phase 3 EUCTR2021-000292-37-FR France
Dexamethasone and rituximab
Copenhagen University Hospital at Herlev
2004 Phase 3 NCT00909077 Denmark
Dexamethasone combined with romiplostim N01
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06658834 China
Dexamethasone monotherapy
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06992128 China
2024 Phase 2 NCT06658834 China
Dexamethasone oral
Yunfeng Cheng
2024 - NCT06479317 China;Hong Kong;Macau
Dexamethasone palmitate
Nakayama Takayuki
2019 Phase 1 JPRN-jRCTs041190069 -
Dexamethasone USP micronized
New England Research Institutes
2010 Phase 3 NCT00991939 United States
Diammonium glycyrrhizinate enteric-coated capsule
Shandong University
2021 Phase 2 NCT05023915 China
Difenidramina cloridrato
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Discontinuation OF eltrombopag
Weill Medical College of Cornell University
2011 - NCT01386723 United States
Doptelet 20 MG FILM-coated tablets
Dova Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Sobi, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE France;Germany;Hungary;Poland;Russian Federation;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Doxil
Hematology and Oncology Specialists
2001 Phase 2 NCT00107913 United States
Drug therapy FOR ITP
Ain Shams University
2013 Phase 2/Phase 3 NCT01763658 Egypt
Dyphenhydramine hydrochloride
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
DZD8586 dose level 1
Dizal Pharmaceuticals
2026 Phase 2 NCT07294365 China
DZD8586 dose level 2
Dizal Pharmaceuticals
2026 Phase 2 NCT07294365 China
DZD8586 dose level 3
Dizal Pharmaceuticals
2026 Phase 2 NCT07294365 China
E5501
Eisai Inc.
2011 Phase 1 NCT01437384 United States
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
E5501 40 MG 2 X 20-MG tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
E5501 40 MG 2 X 20-MG tablets, orally, with food
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
E5501 40MG 2 X 20-MG tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
Efgartigimod
ARGENX BV
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom
Jaume Ayguasanosa
2020 Phase 3 JPRN-jRCT2011220037 Austria;Belgium;Bulgaria;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russia;Spain;The Czech Republic;The Netherlands;The United Kingdom;The United States;Turkey;Ukraine
argenx
2020 Phase 3 NCT04274452 United States
2020 Phase 3 NCT04225156 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russia;Spain;Turkey (Türkiye);Ukraine;United Kingdom;United States
2019 Phase 3 NCT04188379 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BV
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod alfa
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
Gandini Domenica
2022 Phase 3 JPRN-jRCT2071210087 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Latvia;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
Efgartigimod alpha
argenx BVBA
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod IV
argenx
2025 Phase 2/Phase 3 NCT07194850 Germany;Italy;Poland;Romania;Spain;United Kingdom
2024 Phase 3 NCT06544499 Austria;Bulgaria;China;Croatia;Czechia;France;Germany;Hungary;Ireland;Italy;Poland;Portugal;Romania;Serbia;Spain;United Kingdom;United States
Efgartigimod PH20 SC
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx
2021 Phase 3 NCT04812925 Argentina;Australia;Bulgaria;Chile;China;Georgia;Greece;Ireland;Italy;Japan;Jordan;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russia;South Africa;South Korea;Thailand;Tunisia;Turkey (Türkiye);United Kingdom;United States
2020 Phase 3 NCT04687072 Argentina;Australia;Bulgaria;Chile;China;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
Eltrombopag
Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan
2016 Phase 3 NCT02877212 Pakistan
Assiut University
2019 Phase 4 NCT04102033 -
Baylor College of Medicine
2019 Phase 3 NCT03939637 United States
Beijing Children Hospital, Capital Medical University
2021 Phase 4 ChiCTR2100048162 China
Eisai Inc.
2012 Phase 3 NCT01433978 United States
Fuyang People's hospital
2024 Phase 4 ChiCTR2500095156 China
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline
2012 Phase 3 NCT01520909 Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2010 - NCT01439321 -
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
2009 - NCT01236014 -
2009 Phase 2 NCT00908037 Canada;France;Netherlands;Spain;United Kingdom;United States
2007 Phase 2 NCT00424177 Australia;Canada;Germany;India;Korea, Republic of;Netherlands;Russian Federation;Spain;Tunisia;United Kingdom;United States
2006 Phase 3 NCT00370331 Austria;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;Ukraine;United Kingdom;United States;Vietnam
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2004-000367-98-DK Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-SE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-EE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 Phase 2 NCT02402998 Italy
2016 - NCT02298075 Italy
Hagaziekenhuis
2017 Phase 4 EUCTR2016-004295-22-NL Canada;Netherlands
Hematology/ Oncology, Iwate Medical University
2013 - JPRN-UMIN000011396 Japan
Hospital Universitario Dr. Jose E. Gonzalez
2015 Phase 2 NCT02834286 Mexico
Humanity & Health Medical Group Limited
2018 Phase 2 NCT03830749 Hong Kong
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria
Institute of Hematology & Blood Diseases Hospital, China
2022 Phase 4 NCT05583838 China
2018 Phase 2 NCT03664518 China
Jikei University school of Medicine
2011 - JPRN-UMIN000006150 Japan
McMaster University
2012 Phase 3 NCT01621204 Canada;Netherlands
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Novartis Pharma. K.K.
2020 Phase 2 JPRN-jRCT2080225175 Asia except Japan;Europe;Japan;North America;South America
Novartis Pharmaceuticals
2023 Phase 3 NCT05653219 Argentina;Australia;Austria;Belgium;China;Czechia;France;Germany;Hungary;India;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;South Korea;Spain;Taiwan;Thailand;Turkey (Türkiye);United Kingdom;United States
2020 Phase 2 NCT04346654 Germany
2018 Phase 2 NCT03524612 Austria;Brazil;Chile;France;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
2010 - NCT01416311 -
Peking University People's Hospital
2022 Phase 2 NCT05369377 China
2020 Phase 1 NCT04518878 China
2020 Phase 2 NCT04516837 China
2020 - NCT04214951 China
Shanghai Sixth People's Hospital
2019 Phase 4 ChiCTR1900021755 China
Sohag University
2025 - NCT07093606 Egypt
The First Affiliated Hospital of Zhejiang Chinese Medical University
2026 - ChiCTR2600125760 China
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China
The Second Affiliated Hospital of Kunming Medical University
2021 Phase 4 ChiCTR2100051890 China
2020 Phase 4 ChiCTR2000030603 China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025 Phase 4 NCT07189910 China
University Hospital, Macau
2015 - ChiCTR1900021211 China
Weill Medical College of Cornell University
2013 Phase 2 NCT01880047 United States
2009 Phase 2 NCT00902018 United States
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China
Yamauchi Kyosuke
2023 Phase 3 JPRN-jRCT2031220623 Japan;Singapore
Yunfeng Cheng
2024 - NCT06479291 China;Hong Kong;Macau
Zhejiang Provincial Hospital of Traditional Chinese Medicine
2022 Phase 1 ChiCTR2200058259 China
Eltrombopag 25 MG
Renata PLC
2025 Phase 1/Phase 2 NCT06531018 Bangladesh
Eltrombopag and dexamethasone
Hospital Universitario Dr. Jose E. Gonzalez
2012 Phase 2 NCT01652599 Mexico
Eltrombopag and romiplastim
Assiut University
2023 - NCT06137105 -
Eltrombopag combining rituximab
Institute of Hematology & Blood Diseases Hospital, China
2020 Phase 4 NCT04518475 China
Eltrombopag olamine
FONDAZIONE PROGETTO EMATOLOGIA
2012 - EUCTR2011-004657-11-IT Italy
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy
Fondazione Progetto Ematologia
2012 Phase 2 NCT01610180 Italy
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-000452-18-ES Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma AG
2018 Phase 2 EUCTR2018-000452-18-GR Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-GB Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-AT Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma GmbH
2020 Phase 2 EUCTR2019-002658-21-DE Germany
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
Eltrombopag olamine, revolade, promacta
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Eltrombopag oral tablets
GlaxoSmithKline
2008 Phase 3 NCT00828750 Japan
Eltrombopag pfos
Institute of Hematology & Blood Diseases Hospital, China
2026 - NCT07476846 -
Eltrombopag plus diacerein
Qilu Hospital of Shandong University
2020 Phase 2 NCT04917679 China
Erythropoietin
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
ESG206
Shanghai Escugen Biotechnology Co., Ltd
2025 Phase 1/Phase 2 NCT06853444 China
Estimation OF serum level OF IL17
Sohag University
2022 - NCT05371743 Egypt
Estimation OF serum level OF IL2
Sohag University
2022 - NCT05371743 Egypt
ETB115
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-000452-18-ES Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma AG
2018 Phase 2 EUCTR2018-000452-18-GR Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-GB Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-AT Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma GmbH
2020 Phase 2 EUCTR2019-002658-21-DE Germany
Ethanolamine
Pingdingshan First People's Hospital
2024 Phase 4 ChiCTR2400090793 China
West China Hospital,Sichuan University
2022 Phase 2 ChiCTR2200065074 China
Fecal microbiome
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Fecal microbiota transplantation
Chinese University of Hong Kong
2019 - NCT04014413 Hong Kong
Filgrastim
Fairview University Medical Center
2000 - NCT00006055 United States
Fludarabine phosphate
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2026 Phase 2 NCT07603557 Denmark;Germany;United Kingdom;United States
Fostamatinib
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2023 - NCT06071520 Spain
Gruppo Italiano Malattie EMatologiche dell'Adulto
2023 - NCT05613296 Italy
Kissei Pharmaceutical Co., Ltd.
2023 - NCT06757257 Japan
2019 Phase 3 JPRN-jRCT2080224916 Japan
Miyakawa Yoshitaka
2026 - JPRN-jRCTs031250344 -
Rigel Pharmaceuticals
2021 - NCT04904276 United States
Fostamatinib disodium
Rigel Pharmaceuticals
2015 Phase 3 NCT02076412 Austria;Bulgaria;Czech Republic;Czechia;Germany;Norway;Poland;Romania;Spain;United States
2014 Phase 3 NCT02077192 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Hungary;Italy;Netherlands;Norway;Poland;Romania;Spain;United Kingdom;United States
2014 Phase 3 NCT02076399 Australia;Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Fostamatinib disodium / R935788
Rigel Pharmaceuticals
2007 Phase 2 NCT00706342 United States
Fostamatinib disodium 100 MG
Rigel Pharmaceuticals
2018 - NCT03363334 -
Fostamatinib disodium 150 MG
Rigel Pharmaceuticals
2018 - NCT03363334 -
Fostamatinib disodium tablets
Rigel Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2013-005454-30-PL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-IT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-ES Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005453-76-ES Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2015 Phase 3 EUCTR2013-005452-15-HU Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-NL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-GB Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-DK Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-CZ Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-BG Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-AT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005453-76-PL Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-CZ Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-BG Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-AT Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005452-15-NL Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-IT Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-GB Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-DK Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
G-CSF
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Gammaplex
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States
Gammaplex, intravenous immunoglobulin
Bio Products Laboratory
2007 Phase 3 NCT00504075 Argentina;India;United States
GL-2045
Gliknik Inc.
2026 Phase 1 NCT07605845 United Kingdom
Global DNA methylation will BE quantified IN THE DNA samples BY colorimetry
Assiut University
2019 - NCT04100876 -
Glycyrrhetinic acid
Shandong University
2019 Phase 4 NCT03998982 China
GMA161
Genzyme, a Sanofi Company
2005 Phase 1 NCT00244257 United States
GNR-069
AO GENERIUM
2022 Phase 3 NCT05492409 Russian Federation
2021 Phase 3 NCT05220878 Russian Federation
GP404141
Geropharm
2023 Phase 3 NCT06497036 Russian Federation
GSK1550188
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2022 Phase 3 EUCTR2021-000006-16-FR France;Italy;Norway;Spain
GlaxoSmithKline Research & Development Limited
2012 - EUCTR2011-000241-21-DE Germany;United Kingdom
2011 - EUCTR2011-000241-21-GB Germany;United Kingdom
H. pylori triple therapy
Federal University of São Paulo
2008 Phase 2/Phase 3 NCT01730352 Brazil
HBM9161 dose A
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China
HBM9161 dose B
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China
HD-DXM
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
Shandong University
2022 Phase 2 NCT05411874 -
Healthy controls
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Herombopag
Jiangsu HengRui Medicine Co., Ltd.
2023 Phase 3 NCT05685420 -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025 - ChiCTR2500097299 China
Yin Jie
2022 Phase 3 NCT05328804 China
Herombopag olamine tablets
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06838949 China
Southern Medical University Southern Hospital
2025 - ChiCTR2500106843 China
Hetrombopag
Fuyang People's hospital
2024 Phase 4 ChiCTR2500095156 China
Jiangsu HengRui Medicine Co., Ltd.
2021 Phase 3 NCT04737850 China
The First Affiliated Hospital of Xi'an Jiaotong University
2024 - ChiCTR2500095505 China
West China Hospital, Sichuan University
2025 - ChiCTR2500096457 China
Wuhan Union Hospital, China
2022 - NCT05333861 China
Hetrombopag 5MG PO QD
Shandong University
2023 Phase 2 NCT05943691 China
Hetrombopag olamine
Jiangsu HengRui Medicine Co., Ltd.
2018 Phase 1 NCT03603132 China
2015 Phase 1 NCT02614846 China
2014 Phase 1 NCT02403440 China
Peking Union Medical College Hospital
2024 Phase 2 NCT06478537 China
Hiberix - polvere E solvente PER soluzione iniettabile PER USO intramuscolare 1 flaconcino DI polvere + 1 siringa preriempita DI solvente DA 0.5 ML
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
High dose dexamethasone
Peking University People's Hospital
2025 Phase 1 NCT07315373 -
High dose dexamethasone pulses
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of
HIGH-dose dexamethasone
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
HenanCancerHospital
2026 - ChiCTR2600120287 China
Shandong University
2023 Phase 2 NCT05943691 China
Subei People's Hospital of Jiangsu province.
2025 Phase 2 ChiCTR2500105480 China
The First Affiliated Hospital of Xi'an Jiaotong University
2024 - ChiCTR2500095505 China
The Second Affiliated Hospital of Guangxi Medical University
2023 Phase 4 ChiCTR2100053604 China
HIGH-dose dexamethasone combined with orelabrutinib
Shandong University
2026 Phase 3 NCT07559331 China
Higher dose OF rituximab
Weill Medical College of Cornell University
2003 Phase 2/Phase 3 NCT00774202 United States
HMPL-523
Hutchison Medipharma Limited
2019 Phase 1 NCT03951623 China
Hutchmed
2024 Phase 1 NCT06291415 Australia;Germany;Norway;Spain;United States
2021 Phase 3 NCT05029635 China
Honey
mamdouh abdulmaksoud abdulrhman
2014 - NCT01462916 Egypt
Huaiqihuang granule
Qidong Gaitianli Medicines Co., Ltd
2017 Phase 4 NCT03201848 China
Human immunoglobulin
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
2020 Phase 3 ChiCTR2300069388 China
LFB BIOTECHNOLOGIES
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Octapharma AG
2007 Phase 3 EUCTR2005-003552-35-FR Austria;Czech Republic;France;Germany
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
ZLB Behring AG
2004 - EUCTR2004-000537-11-DE Germany;Italy
Human immunoglobulin (PH4) FOR intravenous injection
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
2025 Phase 3 NCT07233213 Turkey (Türkiye)
Human immunoglobulin G
Octapharma AG
2006 - EUCTR2005-003552-35-DE Czech Republic;France;Germany
2006 - EUCTR2005-003552-35-AT Austria;Czech Republic;France;Germany
Human immunoglobulin intravenous
Green Cross Corporation
2014 Phase 3 NCT02063789 Korea, Republic of
Human normal immunoglobulin
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2021 Phase 3 EUCTR2021-000292-37-FR France
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands
Human normal immunoglobulin FOR intravenous USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Human normal immunoglobulin FOR intrvenous USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Humax-CD38
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
Hydroxychloroquine
Assiut University
2017 Phase 4 NCT03229746 Egypt
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China
The Second Affiliated Hospital of Kunming Medical University
2023 Phase 4 ChiCTR2300068387 China
Hydroxychloroquine oral tablet
Yunfeng Cheng
2024 - NCT06479317 China;Hong Kong;Macau
2024 - NCT06479304 China;Hong Kong;Macau
2024 - NCT06479291 China;Hong Kong;Macau
Hypersialylated immunoglobulin
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
I10E
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Ianalumab
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001672-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2023 Phase 3 EUCTR2022-001627-32-ES Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-ES Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-RO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-NO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-BG Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-FR Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-BE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-CZ Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-CZ Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharmaceuticals
2026 Phase 2 NCT07421167 United States
2026 Phase 2 NCT07039422 Belgium;China;Czechia;France;Germany;Hungary;Italy;Malaysia;Singapore;Spain;Turkey (Türkiye);United Kingdom
2025 - NCT07244289 -
2023 Phase 2 NCT05885555 Argentina;Australia;China;Czechia;France;Germany;Italy;Malaysia;Poland;South Korea;Spain;Turkey (Türkiye);United Kingdom;United States
2023 Phase 3 NCT05653349 Argentina;Australia;Austria;Belgium;Bulgaria;China;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey (Türkiye);United Kingdom;United States;Vietnam
2023 Phase 3 NCT05653219 Argentina;Australia;Austria;Belgium;China;Czechia;France;Germany;Hungary;India;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;South Korea;Spain;Taiwan;Thailand;Turkey (Türkiye);United Kingdom;United States
Yamauchi Kyosuke
2023 Phase 3 JPRN-jRCT2061220095 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;China;Czech Republic;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Vietnam
2023 Phase 3 JPRN-jRCT2031220623 Japan;Singapore
Ianalumabproduct code: VAY736pharmaceutical form: concentrate FOR solution FOR infusioninn or proposed INN: ianalumabcurrent sponsor code: VAY736concentration unit: MG/ML milligram(S)/millilitreconcentration type: equalconcentration number: 150-pharmaceutical form OF THE placebo: concentrate FOR solution FOR infusionroute OF administration OF THE placebo: intravenous USE
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-FR Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
IG vena 100 ML vial
Kedrion SpA
2013 - EUCTR2013-000961-36-IT Italy
IG vena 50 G/L solution FOR infusion 100 ML vial + infusion SET
Kedrion SpA
2013 Phase 3 EUCTR2013-000961-36-DE Germany;Italy
IGG next generation
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
IGIV3I grifols
Grifols Biologicals Inc.
2008 Phase 3 NCT00511147 Canada;India;Puerto Rico;United States
Instituto Grifols, S.A.
2008 Phase 3 NCT00699140 Russian Federation;Spain;United Kingdom
Igpro10
CSL Behring
2011 Phase 4 NCT01390649 Bulgaria;Poland;Romania;Serbia
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
ZLB Behring AG
2004 - EUCTR2004-000537-11-DE Germany;Italy
Iguratimod
Peking University People's Hospital
2025 Phase 2 NCT07057778 China
2022 Phase 2 NCT05302024 China
2021 Phase 2 NCT05281068 China
Immune globulin intravenous
Baxalta now part of Shire
2002 Phase 3 NCT00157079 United States
Immune globulin intravenous (human), 10% triple virally reduced solution
Baxalta now part of Shire
2003 Phase 2 NCT00162006 Czech Republic;Czechia;Germany;Hungary;Poland
Immunglobulin
Octapharma AG
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Immunoglobulin
CSL Behring
2004 Phase 3 NCT00168038 Germany;Italy;Poland;Russian Federation;Switzerland;Ukraine;United Kingdom
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine
2014 Phase 4 study ChiCTR-IIR-15007523 China
Immunoglobulin G
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland
Octapharma AG
2013 Phase 3 EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Immunoglobulina umana normale
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
Inactivated trivalent influenza vaccine
Neufeld, Ellis J, MD, PhD
2004 - NCT01713855 United States
Inaticabtagene autoleucel injection
Juventas Cell Therapy Ltd.
2025 Phase 1 NCT06826430 China
INCA000585
Incyte Corporation
2025 Phase 2 NCT07104565 Australia;France;Italy;Netherlands;Spain;United Kingdom;United States
Interleukin 2
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT01988506 France
Intravenous immunoglobulin
Fujian Medical University Union Hospital
2022 Phase 4 NCT05520892 China
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Peking University People's Hospital
2023 Phase 2 NCT05634824 -
Intravenous immunoglobulin (ivig), 10% solution FOR infusion
Biopharma Plasma LLC
2022 Phase 3 NCT05422365 Ukraine
Intravenous immunoglobulins
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT04968899 France
Iptacopan
Novartis Farmacéutica, S.A.
2021 Phase 2 EUCTR2021-002039-40-ES Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Novartis Pharmaceuticals
2021 Phase 2 NCT05086744 Germany;Italy;South Korea;Spain;United Kingdom;United States
Iptacopan hydrochloride
Novartis Pharma AG
2021 Phase 2 EUCTR2021-002039-40-DE Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Ivig
Baylor College of Medicine
2019 Phase 3 NCT03939637 United States
Kedrion S.p.A.
2025 Phase 3 NCT07059000 Czechia;Germany;Italy;Romania;Serbia;Spain;Turkey (Türkiye);United States
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Peking University People's Hospital
2023 Phase 2 NCT06577909 China
Ivig infusion
McMaster University
2012 Phase 3 NCT01621204 Canada;Netherlands
IVIG-L
Sanquin
2001 Phase 3 NCT00151840 Poland
JCXH-213
The General Hospital of Western Theater Command
2026 Phase 1 NCT07622329 -
KardéGIC
CHU Toulouse
2021 Phase 4 EUCTR2020-000968-30-FR France
KZR-616
Kezar Life Sciences, Inc.
2020 Phase 2 NCT04039477 Australia;Italy;Poland;Russian Federation;United States
L01fc01
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
Laboratory test
Assiut University
2025 - NCT07059910 -
Lactate dehydrogenase
Sohag University
2025 - NCT07046013 -
Lansoprazole, clarithromycin, amoxycillin
Mahidol University
2006 Phase 4 NCT00467571 Thailand
Levofloxacin-based H. pylori eradication therapy
Al-Mustansiriyah University
2024 - NCT07150286 Iraq
LGD-4665
GlaxoSmithKline
2008 Phase 2 NCT00621894 United States
LIV-gamma SN INJ.
SK Plasma Co., Ltd.
2019 Phase 3 NCT05566990 Korea, Republic of
LNP023
Novartis Farmacéutica, S.A.
2021 Phase 2 EUCTR2021-002039-40-ES Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Novartis Pharma AG
2021 Phase 2 EUCTR2021-002039-40-DE Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
LOW-dose rituximab
Peking University People's Hospital
2025 Phase 2 NCT07057778 China
Luspatercept
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Lusutrombopag
Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
2024 Phase 4 ChiCTR2400080388 China
Shionogi
2010 Phase 2 NCT01129024 United States
Lusutrombopag oral tablet
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06287567 China
Lymphostat B
GlaxoSmithKline Research & Development Limited
2012 - EUCTR2011-000241-21-DE Germany;United Kingdom
2011 - EUCTR2011-000241-21-GB Germany;United Kingdom
M254
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
Mabthera
Assistance Publique - Hôpitaux de Paris
2017 - NCT03154385 France
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
Ostfold Hospital Trust
2006 Phase 3 NCT00344149 Norway
ROCHE
2005 - EUCTR2005-000859-15-IT Italy
Rikshospitalet
2010 Phase 3 EUCTR2005-005918-20-GB France;Sweden;United Kingdom
2008 Phase 3 EUCTR2005-005918-20-FR France;Sweden;United Kingdom
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Sykehuset Østfold, Fredrikstad
2009 Phase 3 EUCTR2005-005918-20-SE France;Sweden;United Kingdom
University Hospital, Toulouse
2009 - NCT00960713 France
MabthéRA
Assistance Publique - Hôpitaux de Paris
2003 Phase 2 NCT00225875 France
Medical standard OF care FOR ITP
Amgen
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Menveo – polvere E soluzione PER soluzione iniettabile
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Methylprednisolone
Fairview University Medical Center
2000 - NCT00006055 United States
Fujian Medical University Second Hospital
2015 Phase 4 study ChiCTR-IPR-15006397 China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
2016 Phase 4 study ChiCTR-IIR-16008994 China
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Methylprednisolone and ivig
The Hospital for Sick Children
2005 Phase 3 NCT00376077 Canada
Metilprednisolone
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Metronidazole
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
Mezagitamab
Shikamura Mitsuhiro
2025 Phase 3 JPRN-jRCT2031250237 Australia;Bulgaria;China;Croatia;Czech Republic;France;Germany;Greece;Hong Kong;Italy;Japan;Netherlands;Norway;Poland;South Korea;Spain;Sweden;Turkey;United Kingdom;United States
2025 Phase 3 JPRN-jRCT2031240667 Australia;China;Hong Kong;Japan;South Korea;Turkey;United Kingdom;United States
Takeda
2025 Phase 3 NCT06948318 Australia;Bulgaria;China;Croatia;Hong Kong;Italy;Japan;Netherlands;Poland;South Korea;Spain;Turkey (Türkiye);United Kingdom;United States
2025 Phase 3 NCT06722235 Australia;Bulgaria;China;Croatia;France;Greece;Hong Kong;Italy;Japan;Netherlands;Norway;Poland;South Korea;Spain;Sweden;Turkey (Türkiye);United Kingdom;United States
Takeda Development Center Americas, Inc. (Takeda)
2022 Phase 2 EUCTR2019-004103-12-GR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-HR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
MINI-pool ivig
Assiut University
2025 - NCT07068126 Egypt
MK-8723
Merck Sharp & Dohme Corp.
2013 Phase 1 NCT01963260 Australia;Georgia;Israel;Moldova, Republic of
Montelukast
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China
Mycophenolate mofetil
The First Affiliated Hospital of Dalian Medical University
2014 - ChiCTR-TRC-14004514 China
University Hospitals Bristol NHS Foundation Trust
2017 Phase 3 EUCTR2017-001171-23-GB United Kingdom
University Hospitals Bristol and Weston NHS Foundation Trust
2017 Phase 3 NCT03156452 United Kingdom
Weill Medical College of Cornell University
2016 Phase 3 NCT02649504 -
Mycophenolate mofetil (MMF) treatment
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
2023 Phase 3 NCT06288932 Pakistan
Nanogam
Hagaziekenhuis
2017 Phase 4 EUCTR2016-004295-22-NL Canada;Netherlands
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands
Neofordex
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT04968899 France
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
Neofordex 40 MG compriméS
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2021 Phase 3 EUCTR2021-000292-37-FR France
Newgam
Octapharma
2011 Phase 3 NCT01349790 Germany
Octapharma AG
2013 Phase 3 EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
NGS
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Nicotinamide adenine dinucleotid/nicotinamide mononucleotide
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 1/Phase 2 NCT06776510 China
Nimenrix
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Ninlaro
Assistance Publique - Hôpitaux de Paris
2019 Phase 2 NCT03965624 France
Nplate
AO GENERIUM
2021 Phase 3 NCT05220878 Russian Federation
Amgen Inc
2015 Phase 3 EUCTR2011-005019-96-PL Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-HU Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-GB Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-CZ Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-BE Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
- - EUCTR2011-005019-96-Outside-EU/EEA Australia;Brazil;Canada;Israel;Mexico;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
- Phase 3 EUCTR2011-005019-96-FR Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
- Phase 3 EUCTR2011-005019-96-ES Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
- - EUCTR2010-018426-39-Outside-EU/EEA Australia;Canada;United States
- - EUCTR2009-016203-32-Outside-EU/EEA Australia;Canada;United States
Geropharm
2023 Phase 3 NCT06497036 Russian Federation
Nplate 500 microgramos polvo para solucióN inyectable
Amgen Inc
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom
NVG-2089
Nuvig Therapeutics, Inc.
2025 Phase 2 NCT07095127 United States
Obinutuzumab
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 2 NCT06094881 China
2023 Phase 2 NCT05995054 China
OM336
Ouro Medicines
2025 Phase 1 NCT07083960 Australia
Orelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
2023 Phase 3 NCT06004856 China
2022 Phase 2 NCT05232149 China
HenanCancerHospital
2026 - ChiCTR2600120287 China
Peking Union Medical College Hospital
2026 Phase 2 NCT07400250 China
Shandong University
2021 Phase 2 NCT05020288 -
Oseltamivir
Fujian Children's Hospital
2023 Phase 2 ChiCTR2300071184 China
Shandong University
2016 Phase 2 NCT01965626 China
St. Michael's Hospital, Toronto
2016 Phase 3 NCT03520049 Canada
Panzyga
Octapharma
2020 Phase 4 NCT03866798 United States
Paracetamolo
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Peripheral blood and bone marrow withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
2023 - NCT05694325 Italy
PF-06755347 intravenous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06755347 subcutaneous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06755347 subcutaneous ITP
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06835375
Pfizer
2022 Phase 2 NCT05070845 Australia;Canada;Czechia;Hungary;Poland;United Kingdom;United States
Pfizer Inc.
2022 Phase 2 EUCTR2021-002897-19-HU Australia;Canada;Czech Republic;Czechia;Hungary;Poland;United States
2022 Phase 2 EUCTR2021-002897-19-CZ Australia;Canada;Czech Republic;Czechia;Hungary;Poland;United States
PG2
PhytoHealth Corporation
2008 Phase 2 NCT00860600 Taiwan
Pirtobrutinib
Eli Lilly and Company
2025 Phase 1/Phase 2 NCT06721013 China;Denmark;France;Italy;Norway;Poland;South Korea;Spain;United Kingdom;United States
Plasma RNA isolation, qpcr analysis OF micro RNA
Sohag University
2022 - NCT05371743 Egypt
Platelet concentrate
Shandong University
2018 Phase 3 NCT03492515 China
PN20
Chongqing Peg-Bio Biopharm Co., Ltd.
2022 Phase 1 NCT06523088 China
PN20 treatment
Chongqing Peg-Bio Biopharm Co., Ltd.
2025 Phase 1 NCT06880081 China
Povetacicept
Alpine Immune Sciences, Inc.
2023 Phase 1/Phase 2 NCT05757570 Australia;Austria;Canada;Germany;Italy;Norway;Spain;Turkey (Türkiye);United Kingdom;United States
Prednisolon
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
Prednisolone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of
Renata PLC
2025 Phase 1/Phase 2 NCT06531018 Bangladesh
University Hospitals Bristol and Weston NHS Foundation Trust
2017 Phase 3 NCT03156452 United Kingdom
Prednisone
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2021 Phase 3 EUCTR2021-000292-37-FR France
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-IIR-17012850 China
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
2013 - ChiCTR-TRC-13003602 China
Fairview University Medical Center
2000 - NCT00006055 United States
Fujian Medical University Union Hospital
2022 Phase 4 NCT05522465 China
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Huizhou Municipal Central Hospital
2022 Phase 4 ChiCTR2100053452 China
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of
Mayo Clinic
2007 Phase 0 NCT00486421 United States
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
New England Research Institutes
2010 Phase 3 NCT00991939 United States
Peking University People's Hospital
2023 Phase 2 NCT06577909 China
2021 Phase 2 NCT05333744 China
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine
2014 Phase 4 study ChiCTR-IIR-15007523 China
Shandong University
2010 Phase 4 NCT01356511 China
Shanghai University of Traditional Chinese Medicine affiliated Yueyang Hospital of traditional Chinese and Western Medicine
2017 - ChiCTR-IOR-16010001 China
Shanxi Province People‘s Hospitall
2025 Phase 0 ChiCTR2500101851 China
Subei People's Hospital of Jiangsu province.
2025 Phase 2 ChiCTR2500105480 China
The Second Affiliated Hospital of Guangxi Medical University
2023 Phase 4 ChiCTR2100053604 China
The Second Affiliated Hospital of Kunming Medical University
2023 Phase 4 ChiCTR2300068387 China
University Hospital, Essen
2002 Phase 3 NCT02334813 -
Zhejiang Provincial Hospital of Traditional Chinese Medicine
2022 Phase 1 ChiCTR2200058259 China
Prednisone (cortancyl®) alone followed BY monitoring and standard OF care
Assistance Publique - Hôpitaux de Paris
2015 Phase 3 NCT02627417 France
Prednisone acetate
Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine
2016 - ChiCTR-INR-16009028 China
2015 - ChiCTR-OCB-15006981 China
Dongzhimen Hospital of Beijing University of Chinese Medicine
2016 Phase 1 study ChiCTR-IIR-16009020 China
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2023 - ChiCTR2300071394 China
Prednisone tablet
Yunfeng Cheng
2024 - NCT06479304 China;Hong Kong;Macau
PRG-1801
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024 Early Phase 1 NCT06519565 China
Privigen
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
PRN1008
Principia Biopharma Inc.
2020 Phase 3 EUCTR2020-002063-60-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, Inc.
2021 Phase 3 EUCTR2020-002063-60-NO Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-HU Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-FR Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-AT Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002063-60-DE Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Türkiye;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-PL Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-GB Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Tanaka Tomoyuki
2022 Phase 3 JPRN-jRCT2051220003 Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Republic of Korea;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
PRN1008 100 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-GB Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
PRN1008 300 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-GB Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
PRN1008 400 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-GB Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Probiotic agent
Shandong University
2017 Phase 2 NCT03033199 China
ProteíNA recombinante estimulante DE LA megacariopoyesis
Amgen Inc.
2007 Phase 2 EUCTR2007-003569-42-ES Spain
Proton pump inhibitor 1 MG/KG/DAY IN 2 divided doses 1 month
Assiut University
2020 Phase 4 NCT03172676 Egypt
PRTX-100
Protalex, Inc.
2015 Phase 1/Phase 2 NCT02566603 France;United Kingdom
2015 Phase 1/Phase 2 NCT02401061 United Kingdom;United States
2007 Phase 1 NCT00571467 Australia;New Zealand
QL0911
Qilu Pharmaceutical Co., Ltd.
2026 Phase 3 NCT07455006 -
2019 Phase 3 NCT05621330 China
QT-019C
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026 Early Phase 1 NCT07416032 China
Quality-OF-life assessment
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Quantitative microbiological test FOR HCV
Assiut University
2019 - NCT04128358 Egypt
R788
Kissei Pharmaceutical Co., Ltd.
2019 Phase 3 NCT04132050 Japan
R935788
Rigel Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2013-005454-30-PL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-IT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-ES Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005453-76-ES Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2015 Phase 3 EUCTR2013-005452-15-HU Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-NL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-GB Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-DK Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-CZ Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-BG Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-AT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005453-76-PL Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-CZ Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-BG Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-AT Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005452-15-NL Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-IT Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-GB Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-DK Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Rapamycin
First Affiliated Hospital of Suzhou Medical College
2011 - NCT01672151 China
RAY121
Chugai Pharmaceutical
2024 Phase 1 NCT06723106 Australia;Austria;Bulgaria;Canada;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey (Türkiye)
2024 Phase 1 NCT06371417 Australia;Austria;Bulgaria;Canada;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey (Türkiye);United States
Recombinant human thrombopoietin
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Institute of Hematology & Blood Diseases Hospital, China
2026 - NCT07476846 -
Peking University People's Hospital
2023 Phase 2 NCT05634824 -
2020 - NCT04214951 China
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine
2014 Phase 4 study ChiCTR-IIR-15007523 China
Shandong University
2018 Phase 3 NCT03492515 China
2014 Phase 3 NCT02139501 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2011 Phase 3 NCT01525836 China
Recombinant human TPO
Peking University People's Hospital
2021 Phase 2 NCT05333744 China
Relovade
GlaxoSmithKline Research and Development Ltd
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
Revolade
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research and Development Limited
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-000452-18-ES Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-GR Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Norway;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-GB Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2018-000452-18-AT Austria;Brazil;Chile;France;Germany;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Saudi Arabia;Spain;Switzerland;Turkey;United Kingdom;United States
Novartis Pharma GmbH
2020 Phase 2 EUCTR2019-002658-21-DE Germany
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland
Revolade 25 MG FILM-coated tablets
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Revolade 50 MG FILM-coated tablets
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Revolade*28CPR RIV 25MG
FONDAZIONE PROGETTO EMATOLOGIA
2012 - EUCTR2011-004657-11-IT Italy
Revolade, promacta
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
RHIL-11
Ming Hou
2011 - NCT01317966 China
RHO(D) immune globulin
Baylor College of Medicine
2019 Phase 3 NCT03939637 United States
Rhtpo
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-OIC-17012859 China
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China
Institute of Hematology & Blood Diseases Hospital, China
2026 - NCT07476846 -
2022 Phase 4 NCT05583838 China
Nanjing Drum Tower Hospital
2024 Phase 0 ChiCTR2400080036 China
Peking Union Medical College
2011 Phase 3 NCT01805648 China
Peking University People's Hospital
2023 Phase 2 NCT05634824 -
2020 Phase 1 NCT04518878 China
2020 Phase 2 NCT04516837 China
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine
2014 Phase 4 study ChiCTR-IIR-15007523 China
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Shandong University
2015 Phase 3 NCT02391272 China
2014 Phase 3 NCT02270801 China
2014 Phase 3 NCT02203422 China
2014 Phase 3 NCT02139501 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2011 Phase 3 NCT01525836 China
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China
Yin Jie
2022 Phase 3 NCT05328804 China
Rhtpo IN combination with rituximab
Ming Hou
2009 Phase 3 NCT01506414 China
Rilzabrutinib
Obara Kentaro
2025 Phase 3 JPRN-jRCT2031250430 -
Principia Biopharma Inc.
2020 Phase 3 EUCTR2020-002063-60-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, Inc.
2021 Phase 3 EUCTR2020-002063-60-NO Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-HU Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-FR Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-AT Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002063-60-DE Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Türkiye;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-PL Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-GB Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2020 Phase 3 NCT04562766 Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 2 NCT03395210 Australia;Bulgaria;Canada;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Sanofi
2025 Phase 3 NCT07216079 Japan
2025 Phase 3 NCT07007962 Austria;France;Hungary;Italy;Poland;Spain;United States
Tanaka Tomoyuki
2022 Phase 3 JPRN-jRCT2051220003 Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Republic of Korea;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Ripertamab/eltrombopag
Wuhan Union Hospital, China
2025 - NCT06790888 -
Rituxan
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
New York Medical College
2021 Phase 1 NCT04323748 United States
University Hospital, Toulouse
2009 - NCT00960713 France
Rituxan, cyclophosphamide, vincristine, prednisone
Weill Medical College of Cornell University
2003 Phase 2/Phase 3 NCT00774202 United States
Rituximab
Assistance Publique - Hôpitaux de Paris
2017 - NCT03154385 France
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR1900027748 China
Fujian Children's Hospital
2022 Phase 0 ChiCTR2200061828 China
Hamilton Health Sciences Corporation
2006 Phase 2 NCT00372892 Canada
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
2005 Phase 3 NCT00770562 Italy
Hospital Universitario Dr. Jose E. Gonzalez
2015 Phase 2 NCT02834286 Mexico
Institute of Hematology & Blood Diseases Hospital, China
2026 Phase 2 NCT07362238 China
2026 Phase 2 NCT07362199 China
2026 Phase 2 NCT07297563 China
2026 Phase 2 NCT07234019 China
2012 - NCT01719692 China
Keio University School of Medicine , Yoshitaka miyakawa
2011 Phase 3 JPRN-jRCT1091220070 Japan
Mayo Clinic
2007 Phase 0 NCT00486421 United States
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
Neufeld, Ellis J, MD, PhD
2003 Phase 1/Phase 2 NCT01713738 United States
Ostfold Hospital Trust
2025 Phase 3 NCT07051915 -
2016 Phase 3 NCT03010202 Norway
2006 Phase 3 NCT00344149 Norway
Peking University People's Hospital
2017 Phase 2 NCT03304288 China
ROCHE
2005 - EUCTR2005-000859-15-IT Italy
Rikshospitalet
2008 Phase 3 EUCTR2005-005918-20-FR France;Sweden;United Kingdom
Shandong University
2018 Phase 3 NCT03443570 China
2014 Phase 3 NCT02137681 China
2012 Phase 3 NCT01734057 China
2011 Phase 3 NCT01525836 China
2010 Phase 4 NCT03258866 China
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Sykehuset Østfold, Fredrikstad
2009 Phase 3 EUCTR2005-005918-20-SE France;Sweden;United Kingdom
The First Affiliated Hospital of Soochow University
2025 - NCT07206823 China
The Second Affiliated Hospital of Kunming Medical University
2022 Phase 1 ChiCTR2200057058 China
2021 Phase 4 ChiCTR2100051890 China
2020 Phase 4 ChiCTR2000030603 China
University Hospital, Toulouse
2009 - NCT00960713 France
University of Alabama at Birmingham
2000 Phase 2 NCT00005652 United States
Weill Medical College of Cornell University
2016 Phase 3 NCT02649504 -
2004 Phase 2 NCT00161564 United States
Rituximab and dexamethasone
Hospital Universitario Dr. Jose E. Gonzalez
2010 Phase 2 NCT01107951 Mexico
Rituximab plus methylprednisolone
Peking University People's Hospital
2016 Phase 2 NCT02757196 -
Rocaltrol
Shandong University
2020 Phase 4 NCT04094805 China
Romiplostim
Amgen
2014 Phase 3 NCT02279173 Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Hungary;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2012 Phase 3 NCT01444417 Australia;Canada;United States
2010 Phase 2 NCT01143038 Australia;Czech Republic;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
2009 Phase 3 NCT01071954 Australia;Canada;Spain;United States
2009 Phase 4 NCT00907478 Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;United States
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2005 Phase 3 NCT00508820 Australia;Austria;Belgium;Canada;Czech Republic;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom;United States
2004 Phase 3 NCT00116688 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2002 Phase 1/Phase 2 NCT00117143 -
2002 Phase 2 NCT00111475 -
Amgen Inc
2015 Phase 3 EUCTR2011-005019-96-PL Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-HU Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-GB Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-CZ Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2014 Phase 3 EUCTR2011-005019-96-BE Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
- - EUCTR2011-005019-96-Outside-EU/EEA Australia;Brazil;Canada;Israel;Mexico;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
- Phase 3 EUCTR2011-005019-96-FR Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
- Phase 3 EUCTR2011-005019-96-ES Australia;Belgium;Brazil;Canada;Czech Republic;France;Hungary;Israel;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
- - EUCTR2010-018426-39-Outside-EU/EEA Australia;Canada;United States
- - EUCTR2009-016203-32-Outside-EU/EEA Australia;Canada;United States
Chinese Academy of Medical Science Hematology Hospital
2015 Phase 1+Phase 2 ChiCTR-OPC-15007012 China
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
GlaxoSmithKline
2010 - NCT01439321 -
2009 - NCT01236014 -
Kyowa Kirin China Pharmaceutical Co., Ltd.
2015 Phase 1/Phase 2 NCT02868060 China
Samsung Medical Center
2015 Phase 2 NCT02338414 -
Shanxi Province People‘s Hospitall
2025 Phase 0 ChiCTR2500101851 China
The First Affiliated Hospital of Soochow University
2026 - NCT07612319 China
University Hospital, Basel, Switzerland
2016 Phase 4 NCT02760251 Switzerland
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Romiplostim and danazol
Seoul National University Hospital
2020 Phase 2 NCT04289207 -
Romiplostim N01
Peking Union Medical College Hospital
2026 Phase 2 NCT07400250 China
Qilu Hospital of Shandong University
2024 Phase 4 ChiCTR2400091685 China
The First Affiliated Hospital of Soochow University
2025 - NCT07206823 China
Romiplostim N01 combined with dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06992128 China
Romiplostim plus dexamethasone
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022 Phase 3 NCT05325593 Italy;Spain;United Kingdom
Romiplostin
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 - NCT02298075 Italy
Subei People's Hospital of Jiangsu province.
2025 Phase 2 ChiCTR2500105480 China
Ropivacaine
Huai'an First People's Hospital
2025 Phase 2 ChiCTR2500104776 China
Rozanolixizumab
Sugihara Kazuhiro
2021 Phase 3 JPRN-jRCT2031210245 Austria;Belgium;Bulgaria;Canada;China;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea;Poland;Republic of Moldova;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
UCB Biopharma SRL
2021 Phase 3 NCT04596995 China;Georgia;Germany;Hungary;Italy;Japan;Moldova, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04224688 Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Italy;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04200456 Austria;Belgium;Bulgaria;Croatia;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-jRCT2080225255 Asia except Japan;Europe;Japan;North America
Rozanolixizumabproduct code: UCB7665pharmaceutical form: solution FOR infusioninn or proposed INN: rozanolixizumabcas number: 1584645-37-3current sponsor code: UCB7665concentration unit: MG/ML milligram(S)/millilitreconcentration type: equalconcentration number: 140-pharmaceutical form OF THE placebo: solution FOR infusionroute OF administration OF THE placebo: subcutaneous USE
UCB Biopharma SRL
2020 Phase 3 EUCTR2019-000884-26-FR Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
S-888711
SHIONOGI USA, INC
2010 - EUCTR2009-017942-30-IT France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-016950-42-IT France;Hungary;Italy;United Kingdom
Shionogi
2010 Phase 2 NCT01054443 United States
Shionogi USA, Inc.
2010 - EUCTR2009-017942-30-HU France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-017942-30-GB France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-017942-30-FR France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-017942-30-DE France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-016950-42-HU France;Hungary;Italy;United Kingdom
2010 - EUCTR2009-016950-42-GB France;Hungary;Italy;United Kingdom
2010 Phase 2 EUCTR2009-016950-42-FR France;Germany;Hungary;Italy;United Kingdom
2010 - EUCTR2009-016950-42-DE France;Germany;Hungary;Italy;United Kingdom
SAR444671
Obara Kentaro
2025 Phase 3 JPRN-jRCT2031250430 -
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
SB-497115
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
GlaxoSmithKline Research and Development Limited
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
SB-497115-GR
GLAXO SMITHKLINE
2006 - EUCTR2004-000367-98-IT Denmark;Estonia;Germany;Ireland;Italy;Latvia;Spain;Sweden
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline Research and Development Limited
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
SB-497115-GR 12.5MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB-497115-GR 25MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB-497115-GR 50 MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB497115
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
2005 Phase 2 NCT00102739 Australia;Brazil;Canada;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2004-000367-98-DK Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-SE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-LV Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-IE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 Phase 2 EUCTR2004-000367-98-GB Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 Phase 2 EUCTR2004-000367-98-ES Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-EE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-DE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
GlaxoSmithKline S.A.
2006 - EUCTR2006-000471-14-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline, S.A.
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
2009 - EUCTR2008-006143-40-AT Austria
Search FOR thyroid disorders
Assiut University
2025 - NCT07059910 -
Second line ITP agents
Boston Children's Hospital
2013 - NCT01971684 Canada;United States
Serological assay FOR blood born viral hepatitis
Assiut University
2019 - NCT04128358 Egypt
Serum IL10 BY elisa
Sohag University
2022 - NCT05410249 Egypt
Serum interleukin 10 level
Sohag University
2023 - NCT05835050 Egypt
SHR-2173 injection
Guangdong Hengrui Pharmaceutical Co., Ltd
2025 Phase 1 NCT07206758 China
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States
Chinese SLE Treatment And Research Group
2026 Phase 2/Phase 3 NCT07657793 China
Department of Hematology, Xiniao Hospital
2017 - ChiCTR-ONC-17012126 China
The Second Affiliated Hospital of Army Military Medical University
2022 Phase 4 ChiCTR2100052913 China
Sitagliptin
Peking University People's Hospital
2021 Phase 2 NCT05353673 China
SKI-O-703
Oscotec Inc.
2021 Phase 2 EUCTR2018-003329-26-PL Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 NCT04056195 Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 EUCTR2018-003329-26-GR Greece;Korea, Republic of;Poland;Spain;United States
2019 Phase 2 EUCTR2018-003329-26-ES Greece;Korea, Republic of;Poland;Spain;United States
SM101
SuppreMol GmbH
2010 Phase 1;Phase 2 EUCTR2009-014842-28-BE Belgium;Germany;Poland
SM101 20MG/ML
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine
SM101 5MG/ML
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine
SNP -3279 A/C OF FOXP3
Sohag University
2022 - NCT05410249 Egypt
SNP-924 A/G OF FOXP3
Sohag University
2022 - NCT05410249 Egypt
Spleen sample
Centre Hospitalier Universitaire Dijon
2014 - NCT02821572 France
Spleen samples
Centre Hospitalier Universitaire Dijon
2011 - NCT02042560 France
Standard OF care
Eisai Inc.
2012 Phase 3 NCT01438840 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 NCT01433978 United States
Standard therapy (without eltrombopag): HD-DXM
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland
Steroid and eltrombopage
Assiut University
2025 - NCT07059910 -
Steroids
Baylor College of Medicine
2019 Phase 3 NCT03939637 United States
Safaa AA Khaled
2019 - NCT04113915 -
STSA-1301 subcutaneous injection
Jiangsu BioJeTay Biotechnology Co., Ltd.
2025 Phase 1/Phase 2 NCT06929299 China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
2023 Phase 1 NCT06148389 China
SYM001
Symphogen A/S
2010 Phase 2 EUCTR2007-006081-15-GB Belgium;Germany;India;Israel;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2010 Phase 2 EUCTR2007-006081-15-BE Belgium;Germany;Spain;United Kingdom
2008 Phase 2 NCT00718692 Belgium;Germany;India;Israel;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2008 - EUCTR2007-006081-15-ES Belgium;Germany;Spain;United Kingdom
2008 - EUCTR2007-006081-15-DE Belgium;Germany;Spain;United Kingdom
T cell injection targeting CD19 chimeric antigen receptor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
2024 Early Phase 1 NCT06417398 -
Tacrolimus
Peking University People's Hospital
2021 Phase 2 NCT04747080 China
TAK-079
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Shikamura Mitsuhiro
2025 Phase 3 JPRN-jRCT2031250237 Australia;Bulgaria;China;Croatia;Czech Republic;France;Germany;Greece;Hong Kong;Italy;Japan;Netherlands;Norway;Poland;South Korea;Spain;Sweden;Turkey;United Kingdom;United States
Takeda
2020 Phase 2 NCT04278924 Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Takeda Development Center Americas, Inc. (Takeda)
2022 Phase 2 EUCTR2019-004103-12-GR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-HR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Telitacicept
The Second Affiliated Hospital of Kunming Medical University
2021 Phase 4 ChiCTR2100051890 China
Terbutaline
Peking University People's Hospital
2020 Phase 2 NCT04481282 China
Teriflunomide
Peking University People's Hospital
2025 Phase 2 NCT07065968 China
2023 Phase 2 NCT06190145 China
2023 Phase 2 NCT06176911 China
2023 Phase 2 NCT06176235 China
Thalidomide
Affiliated Hospital of Guangdong Medical University
2017 Phase 2 study ChiCTR-OIC-17012860 China
2017 Phase 2 study ChiCTR-OIC-17012859 China
2017 Phase 2 study ChiCTR-IIR-17012850 China
Shandong University
2013 Phase 2 NCT01976195 China
THE best available therapy
Institute of Hematology & Blood Diseases Hospital, China
2021 Phase 2/Phase 3 NCT04915482 China
Thrombopoietin
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Thrombopoietin receptor agonist
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019 - NCT05931718 Italy
Novartis Pharmaceuticals
2026 Phase 2 NCT07421167 United States
TPO
Peking University People's Hospital
2020 - NCT04214951 China
Shenyang Sunshine Pharmaceutical Co., LTD.
2016 Phase 4 NCT04089267 China
TPO-RA
Institute of Hematology & Blood Diseases Hospital, China
2021 - NCT04890041 China
Nanjing Drum Tower Hospital
2026 - ChiCTR2600117105 China
Novartis Pharmaceuticals
2026 Phase 2 NCT07421167 United States
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025 - ChiCTR2500097299 China
TPO-RA discontinuation
Assistance Publique - Hôpitaux de Paris
2017 Phase 4 NCT03119974 France
TPO-RAS combining ANTI-CD 20 monoclonal antibody
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 4 NCT05718856 China
TQB3473 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025 Phase 2 NCT07083739 China
2025 Phase 3 NCT06900920 China
Treatment : H. pylori eradication
Seoul National University Hospital
2017 Phase 3 NCT03177629 Korea, Republic of
Tretinoin
The First Affiliated Hospital of Xinjiang Medical University
2025 - ChiCTR2500099739 China
Triple therapy
Safaa AA Khaled
2019 - NCT04113915 -
Tysabri
Sahlgrenska University Hospital
2009 Phase 1;Phase 2 EUCTR2008-005871-92-SE Sweden
UCB7665
UCB Biopharma S.P.R.L.
2016 Phase 2 NCT02718716 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
UCB Biopharma SPRL
2017 Phase 2 EUCTR2015-003984-12-LT Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2017 Phase 2 EUCTR2015-003984-12-BG Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-PL Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-ES Australia;Belgium;Bulgaria;Czech Republic;France;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-DE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-BE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
UCB Biopharma SRL
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2016 Phase 2 EUCTR2015-003984-12-IT Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
Universal STAR-T cell
Jian Zhu
2026 Phase 1 NCT07599280 China
Upadacitinib
Peking University People's Hospital
2025 Phase 2 NCT07064889 China
Urine sample
University Hospital, Bordeaux
2019 - NCT04005638 France
Vaccino contro IL memingococco DI gruppo B
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Vaccino haemophilus influenzae B coniugato CON tossoidetetanico
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
VAY736
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001672-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2023 Phase 3 EUCTR2022-001627-32-ES Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-ES Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-RO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-NO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-BG Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-FR Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-BE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-CZ Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-CZ Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Veltuzumab
Gilead Sciences
2007 Phase 1/Phase 2 NCT00547066 United States
Vinblastine
Nanjing Drum Tower Hospital
2024 Phase 0 ChiCTR2400080036 China
Vincristine
Assiut University
2017 Phase 4 NCT03229746 Egypt
VIT D
Mansoura University
2023 Early Phase 1 NCT06073925 -
Vonoprazan
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
Water
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
YTS109 cell injection
China Immunotech (Beijing) Biotechnology Co., Ltd.
2025 Phase 1 NCT06943937 China
Zanubrutinib
He'nan Cancer Hospital
2022 Phase 4 ChiCTR2200060868 China
Institute of Hematology & Blood Diseases Hospital, China
2022 Phase 2 NCT05214391 China
Peking University People's Hospital
2022 Phase 2 NCT05369377 China
2022 Phase 2 NCT05369364 -
2022 Phase 2 NCT05279872 China
The First Affiliated Hospital, College of Medicine, Zhejiang University
2023 Phase 2 ChiCTR2400081061 China
The Second Affiliated Hospital of Kunming Medical University
2022 Phase 1 ChiCTR2200057058 China
Zanubrutinib 160MG/D
Peking University People's Hospital
2025 Phase 1 NCT07315373 -
Zanubrutinib 240MG/D
Peking University People's Hospital
2025 Phase 1 NCT07315373 -
Zanubrutinib 80MG/D
Peking University People's Hospital
2025 Phase 1 NCT07315373 -
Zuberitamab
Union hospital tongji medical college huazhong university of science and technology
2021 Phase 2 ChiCTR2100050513 China